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I. INTRODUCTION 
I.A. RHEUMATOID ARTHRITIS 
A healthy immune system protects the body by attacking foreign bacteria and viruses, 
but an autoimmune disease causes the body to attack healthy tissue. Rheumatoid arthritis 
(RA) is a chronic inflammatory autoimmune disease causing pain, swelling, stiffness and 
loss of function in the joints. In people with Rheumatoid Arthritis, white blood cells 
cause inflammation in the synovium. This causes the tissue that lines the walls of the 
joints to thicken and become swollen and painful when moved. The uncontrollable 
inflammation leads to joint erosion, a loss of motion and damage to many associated 
parts of the body such as lungs, heart
1
. 
a) CAUSES 
Environmental factors, including smoking and pathogens have long been implicated as 
risk factors of rheumatoid arthritis 
2, 3
. 
Genetic Factors 
There are certain genes that may play a small role in the development of rheumatoid 
arthritis, although not directly. People who have one gene in particular, HLA (Human 
Leucocyte Antigen) could be 5 times more likely to get affected by rheumatoid arthritis. 
Research suggests these genes do not cause RA, but might make patients more 
vulnerable to developing it. 
Environmental Factors 
There are several environmental factors that, combined with a genetic predisposition, 
give people a greater risk to develop Rheumatoid Arthritis. These include: 
 Bacteria and viruses 
 Exposure to secondhand smoke 
 Air pollution 
 Insecticides 
There are also several other risks that come from exposure to occupational hazards, such 
as mineral oils and Silica mineral (found in obsidian, granite, diorite, and sandstone) 
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Personal Factors 
Gender: Both men and women are susceptible to rheumatoid arthritis, but the disease is 
far more common in women. In fact, 70 percent of people diagnosed with rheumatoid 
arthritis are women. This may be due to a variety of hormonal factors that are involved in 
the development of Rheumatoid Arthritis. Rheumatoid arthritis symptoms tend to 
improve or disappear completely during pregnancy, but frequent flares are common after 
the birth. Breastfeeding can also cause rheumatoid arthritis symptoms to flare. 
Age: Rheumatoid Arthritis can affect a person at any age, but it typically presents in 
those between the ages of 40-60. 
Family History: Those who have a family history of rheumatoid arthritis may have a 
higher chance of developing the disease. 
b) SYMPTOMS  
c) Common symptoms4, 5 of rheumatoid arthritis are as follows 
 Swollen joints 
 Fatigue 
 Significant weight loss 
 Flulike symptoms and not feeling well 
 Tender, warm, fever 
 Pain and redness 
 
d) PATHOPHYSIOLOGY 
Rheumatoid Arthritis is an autoimmune disease, own body immune system that attacks 
the synovial tissue and other connective tissues. Once the initial immune response is 
triggered, cells of the immune system produce autoantibody and inflammatory cytokines, 
creating a cascade of inflammation. Chronic inflammations of synovial tissue lining of 
the joint capsule result in the proliferation of this tissue. The inflamed proliferating 
synovium in Rheumatoid Arthritis is called as pannus. This pannus invades the cartilage 
and bone surface, producing erosion of bone and cartilage leading to destruction of the 
joint
6
.  
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The normal and Rheumatoid Arthritis joints were depicted in following figure
7
. 
 
 
Fig.No.1: Normal and Rheumatoid Arthritis Joints 
 
 
Development of Arthritis in Rheumatoid Arthritis involved in the following steps
8
 
 
Induction Phase 
Induction phase involves release of antigen-presenting cells (APCs) and the citrulination 
of relevant proteins outside of joints along with monocyte or macrophage infiltration into 
the synovium, and local synovial cells. Fibroblasts and macrophages are activated 
leading to the secretion of proinflammatory cytokines of both the innate and adaptive 
immune systems. 
Inflammation Phase 
Self-antigens, notably citrullinated proteins, are presented in the context of Human 
leucocyte antigen Class II molecules that are characteristic of Rheumatoid Arthritis 
which leads to polyclonal activation of T-cells and B-cells and formation of germinal-
like centers in the synovial tissue. This process is insufficiently controlled by regulatory 
T cells. 
Self-perpetuation 
Cartilage auto antigens (which are not normally accessible to the immune system) 
become exposed by damage and activates the immune system against cartilage tissue 
with further infiltration of pannus into the joints resulting in further destruction. 
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Destruction phase 
Synovial fibroblasts and osteoclasts are activated by pro inflammatory cytokines such as 
TNF-α and IL-6. It may cause destruction of bone and cartilage 
 
Fig.No.2: Stepwise development of arthritis in rheumatoid arthritis. 
e) EPIDEMOLOGY 
 RA has probably received the greatest attention due to the progressive nature of 
its pathogenesis and its tremendous impact on public health and socioeconomics. RA 
affects 0.5-1% of the world population and in India about 15% people i.e. over 180 
million people were affected by RA. This prevalence is higher than many well known 
diseases such as diabetes, AIDS and cancer
9
. 
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f) TREATMENT 
 
 Therapeutic pyramid  
Symptomatic drugs, shows a prompt action on pain and inflammation, but 
without any influence on disease progression.  
 
 Combination therapy 10  
Drugs that could modify the disease course and occasionally induce clinical 
remission - (DMARDs or disease modifying anti-rheumatic drugs) And Anti-
Inflammatory agents such as steroids and Non-steroidal Anti-Inflammatory drugs 
(NSAIDs) are highly effective and should be part of an overall treatment 
program
5
. 
 
g) HISTORY OF ANTI-RHEUMATOID ARTHRITIC DRUGS 
 In olden days treatment for rheumatoid arthritis includes bloodletting, leeching, 
acupuncture, acupressure, moxibustion (use of heat), cupping etc. Heavy metals like 
gold, bismuth, arsenic and copper salts are also used in treatment of rheumatoid arthritis. 
Hippocrates, Galen used Willow extracts (containing salicin) to treat pain of rheumatoid 
arthritis and other forms of arthritis. Aspirin (1853), Salicylic acid (1929), 
Phenylbutazone (1949) and several other Non-steroidal anti-inflammatory agents also 
came into use. Payne in 1895 was the first to suggest the use of Quinine to treat RA. In 
1957 Baguall used chloroquine and now hydroxychloroquine is still part of the Disease-
modifying Anti-Rheumatic drugs ( DMARDs). In 1949, Philip Hench first showed the 
successful use of cortisone in autoimmune diseases including rheumatoid arthritis. 
Methotrexate (1950)-folate antagonist also forms part of the DMARDs
11
. 
 
h) COMMONLY USED DRUGS 
The commonly used drugs for the treatment of the Rheumatoid Arthritis are follows, 
 NSAIDs (Nonsteroidal anti-inflammatory drugs)  
 Ibuprofen, Naproxen sodium, Aspirin, Diclofenac sodium, Celecoxib, 
 Nebumetone, Piroxicam, Indomethazine, Ketoprofen, Salsalate, Sulindac 
 Corticosteroids 
Betamethasone, Prednisone, Dexamethasone, Cortisone, Hydrocortisone, 
Methylprednisolone, Prednisolone 
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 Disease-modifying Anti-Rheumatic drugs (DMARDs) 12 
 
i) NEED FOR NEW ANTI-RHEUMATOID ARTHRITIC DRUGS 
  Some of the reasons necessitating the emergence of newer anti- rheumatoid 
arthritic drugs are 
 To improve the current course of treatment by shortening its total duration. 
 To facilitate drug compliance by providing with less intensive supervision 
 Drug with lesser frequency of administration which permits widely spaced 
intermittent treatment.  
 To reduce the side effects which may include ringing in your ears, stomach 
irritation, heart problems and liver and kidney damage. 
 To design a drug with higher efficacy and more specific in action by 
inhibiting the enzyme target which are responsible for inducing Rheumatoid 
Arthritis. 
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I. B. DRUG DESIGN 
 In the field of new discovery and development, Computational techniques are 
rapidly gaining popularity, implementation and appreciation Drug design is an inventive 
process of finding a new medication based on the knowledge of the biological target also 
known as rational drug design
13
. Drug design is frequently based on computer modeling 
techniques which are often referred to as Computer Aided Drug Design (CADD) 
 Different terms are being applied to this area, including computer aided drug 
design (CADD), computational drug design, computer aided molecular drug design 
(CAMD), computer aided molecular modeling (CAMM), rational drug design, Insilco 
drug design and computer aided rational drug design. Both computational and 
experimental techniques have complementary roles in drug discovery and 
development
14
. 
a) CADD ENTITIES 
 Drug discovery and development process is streamlined by using the computing 
power. 
 Chemical and biological information about ligands, targets in process of 
identification and optimization of new analogs. 
 Design of Insilco filters to eliminate compounds with undesirable properties 
(ADMET) and select the most promising candidates. 
Two types of drug design are as follows, 
1. Ligand Based drug design 
  Ligand based drug design (Indirect drug design) depends on knowledge of all 
other  molecules which binds to the biological target.  
2. Structure based drug design 
Structure based drug design (Direct drug design) mainly depends on knowledge of 
the three dimensional structure of the biological target
15
. 
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b) PHARMACOPHORE MODELING 
 Pharmacophore modeling studies have become one of the major tool in the field 
of drug discovery. In 1909, Paul Ehrlich introduced the concept of Pharmacophore, who 
defined the pharmacophore as „a molecular framework that carries (phoros) the essential 
features responsible for a drug‟s (Pharmacon) biological activity‟.The IUPAC defines “A 
pharmacophore is ensemble of stearic and electronic features that is necessary to ensure 
the optimal supra-molecular interaction with a specific biological target and to trigger or 
block its biological response”16. 
 
Pharmacophore features 
1. Hydrogen bond acceptor 
2. Hydrogen bond donor 
3. Hydrophobic  
4. Hydrophobic aliphatic 
5. Hydrophobic aromatic 
6. Positive ionizable 
7. Negative ionizable 
8. Ring aromatoic 
 In order to identify novel ligands, the pharmacophoric features should match 
different chemical moieties with similar properties. A well-defined pharmacophore 
model includes both hydrophobic volumes and Hydrogen bond vectors. 
 
 Various ligand based and structure based methods involving pharmacophore 
modeling have been developed and extensively applied in the field of virtual screening, 
de nova design and lead optimization. 
 
c) DOCKING STUDIES 
 Virtual screening techniques range from simple one up to sophisticated virtual 
docking methods aimed at fitting putative ligand molecules into the target receptor site
17
. 
In the field of drug design, docking predicts the preferred orientation of one molecule to 
the other when they bound to each other to form a stable complex
18
. Docking plays an 
important role in the molecular modeling as it is used to predict the binding orientation 
(affinity) of drug candidate to their protein targets
19
. 
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1. Docking process 
 The docking process mainly involves the prediction of ligand conformation and 
orientation (posing) with active binding site of the target. Molecular docking process is 
compared to “lock-and-key” model. Here, the protein is considered as the “lock” and the 
ligand as a “key”. The ligand and the protein adjust their conformation to achieve an 
overall “best-fit” which is referred as “induced-fit”20, 21 
2. Docking methodology 
 Docking is an interactive procedure which generates the random ligand 
conformations for specified number of times, number of maximum trials
21
. 
Steps involved in docking  
a. Protein preparation.  
b. Selection of active site (Q-Site finder).  
c. Ligand Preparation. 
d. Docking Procedure. 
e. Visualization / Interpretation of Docking.  
a. Protein preparation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                           Fig.No.3:   Preparation of proteins
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b. Q-site finder 
 Q-site finder an  energy based method for protein ligand binding site prediction. 
During prediction we use the crystal structure of macromolecules (Receptor) with 
small substances (PDB ID: 5FBN) 
 
c. Ligand preparation  
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Fig.No.4: Preparation of ligands 
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d. Docking procedure  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.No.5:  Docking calculations 
e. Visualization of docking results 
 Open molegro viewer 
 File Import molecule Select ligand mapShow interactionSave image as 
ipeg formatPrint screencontrol+cOpen PaintPastesave 
3. GLIDE 10.2 
 GLIDE
 
10.2 (Grid-Based Ligand Docking with Energetic) calculations are 
performed with impact version Maestro 10.2 (L. Schrodinger). Maestro input files of 
both ligands and the active site, including hydrogen atoms for the grid generation. The 
center of the grid enclosing box was defined by the center of the bound ligand as in the 
original PDB entry. The size of the bounding box for placing the ligand center was set to 
12 A
o
 and a scaling factor of 0.9 was also applied to van der waals radii of ligand atoms 
for docking
22
. 
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4. ARGUS LAB 4.1 
 Flexible docking simulation were performed using Argus 4.1 the binding region 
was defined using a grid 32 X 32 X 32 box centered on the centroid of the target. Default 
setting were used for all the remaining parameters. The top 50 poses were generated for 
each ligands. The docking posses were further energy minimized and Docking 
calculation by UFF method and the docking engine is Argus. 
Applications  
Docking is widely used in the field of molecular modeling and may be applied to, 
 Hit identification- docking in combination with scoring function screens 
large databases of potential drugs Insilco to identify newer hits which 
binds to protein target. 
 Lead optimization- used to predict the orientation and conformation of a 
ligand binds to a proteins
23-25
. 
I.C.TARGET ENZYME 
BRUTON’S TYROSINE KINASE (BTK) 
 BTK is a member of the Tec family of cytoplasmic protein tyrosine kinase. It is 
predominantly expressed in hematopoietic cells, including B-cells, but also in cells of 
myeloid lineage such as macrophages, two cell lineages believed to be quite important in 
the treatment of inflammatory arthritis and other autoimmune diseases. BTK contains a 
pleckstrin homology (PH) domain, and Src homology SH3 and SH2 domains. Btk plays 
an important role in B cell development. Activation of B cells by various ligands is 
accompanied by Btk membrane translocation mediated by its PH domain binding to 
phosphatidylinositol-3,4,5-trisphosphate
26-28
. The membrane-located Btk is active and 
associated with transient phosphorylation of two tyrosine residues, Tyr551 and Tyr223. 
Tyr551 in the activation loop is transphosphorylated by the Src family tyrosine kinase, 
leading to autophosphorylation at Tyr223 within the SH3 domain, which is necessary for 
full activation
29,30
. The activation of Btk is negatively regulated by PKC through 
phosphorylation of Btk at Ser180, which results in reduced membrane recruitment, 
transphosphorylation and subsequent activation
31
. The PKC inhibitory signal is likely to 
be a key determinant of the B-cell receptor signaling threshold to maintain optimal Btk 
activity. 
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Mechanism of action  
 Animal models of arthritis suggest that BTK inhibition can result in inhibition of 
B-cell receptor-dependent cell proliferation and a reduction of inflammatory cytokine 
production from myeloid cells (including TNF, IL-1 and IL-6) by preventing signaling 
through the FCyR III receptor
32
. More recently, BTK has been shown to be a key element 
in the signaling pathways induced in macrophages by LPS stimulation of toll-like 
receptor 4 leading to the production of TNF-α, a key cytokine in RA pathogenesis. 
Structure of Bruton’s Tyrosine Kinaase33 
 
Fig.No.6: 3D Structure of BTK 
Here in this study, we used computer aided drug design approaches to identify potent and 
novel inhibitors of BTK which has been considered as an attractive therapeutic target for 
B cell inhibition in  the treatment of Rheumatoid Arthritis.  
CHEMISTRY 
 
14 
 
 
II. SYNTHETIC CHEMISTRY 
 The widespread occurrence of heterocyclic compounds in nature as alkaloids, 
vitamins, pigments in a variety of plants and animal cell constituents; their vital role in 
biological processes; their availability from agriculture wastes and their commercial 
value as solvents, dyes and pharmaceuticals are factors which have drawn the attention 
of organic chemists to this field.  
IMIDAZOLE NUCLEUS 
 Imidazole is a planer five-member heterocyclic ring with 3C and 2N atom and in 
ring N is present in 1st and 3rd positions. Imidazole derivatives have occupied a unique 
place in the field of medicinal chemistry
34
. The high therapeutic properties of the 
imidazole related drugs have encouraged the medicinal chemists to synthesize a large 
number of novel chemotherapeutic agents. Numerous methods for the synthesis of 
imidazole and also their various structure reactions offer enormous scope in the field of 
medicinal chemistry
35
. 
STRUCTURE 
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Fig.No.7: 2D & 3D Structure of Imidazole 
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PHYSIOCHEMICAL PROPERTIES 
 Imidazole are although weak bases, they are stronger bases than the isomeric 
pyrazoles. Like pyrazole, imidazole exhibits tautomerism as a result of which position 4 
& 5 are equivalent
36, 37
. 
  Nature   : Solid 
  Molecular formula  : C3 H4 N2  
  Molecular weight  : 68.0772 
  Melting point   : 89 to 91 °C  
  Boiling point   : 256 °C 
  Solubility   : Solubility in water 
  Density   : 1.23 g/ cm
3 
 
 
SIGNIFICANCE OF SUBSITUTED IMIDAZOLES AS THERAPEUTIC AGENTS 
N
H
N
R
 
2D structure of 4, 5 di phenyl 2-substituted imidazole 
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 It has been estimated that most of the therapeutic agents consists of heterocyclic 
compounds consisting of imidazole nucleus 
 Heterocyclic ring like imidazole in many cases comprises the very core of the active 
moiety or Pharmacophore. 
 During past decades, compounds bearing substituted imidazole have received much 
attention due to their chemotherapeutic value in the development of novel drugs 
 Imidazole and 4,5 di phenyl 2-substituted imidazole has become an important part of 
many Pharmaceuticals.  
 
MEDICINAL USES 
 Substituted imidazoles are widely employed as novel medicinal agents as they are 
found to possess the following  biological activities 
 Anti-tubercular activity.   
 Anti-fungal and Anti-bacterial activity.   
 Anti- inflammatory activity and analgesic activity.  
 Anti- depressant activity  
 Anti-cancer activity  
 Anti-viral activity  
 Anti-leishmanial activity  
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III. LITERATURE REVIEW 
 
The review on following works provided, basic information about the target enzyme 
and designing of its inhibitors. 
1. Rohit Bavi et.al 38 explored and reported some novel Inhibitors for Bruton’s 
Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation. Here 
in this study, 3D QSAR pharmacophore models were generated for BTK based on 
known IC50 values and experimental energy scores with extensive validation by 
subjecting into ADMET properties. Overall, this study suggest that the proposed 
ligands based on the generated Pharmacophore model may be more effective 
inhibitor for Rheumatoid Arthritis.    
 
2. Zhengying Pan D et.al 39 developed a series of certain  Selective Irreversible 
Inhibitors for Bruton’s Tyrosine Kinase using a structural bioinformatics approach. 
Their capabilities to modulate Btk's activity were characterized both In-vitro and In 
vivo. Oral treatment with once-a-day dosing of compound 4 greatly inhibited disease 
development in a rodent rheumatoid arthritis (RA) model. 
 
3. Kyung-Hee Kim et.al40  synthesized and performed the SAR of a series of 
compounds are presented as well as the X-ray crystal structure of the lead 
compound 36 in complex with a gate-keeper variant of ITK enzyme. The lead 
compound showed good In-vivo efficacy in preclinical RA models. 
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NCH3
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N
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N
NH
CH3
 
                    lead compound 36 
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4. Lichuan Liu et.al 41 evaluated the anti-arthritic effect of GDC-0834 [R-N-(3-(6-(4-
(1,4-dimethyl 3-oxopiperazin-2-yl) phenylamino)- 4-methyl-5-oxo-4,5- 
dihydropyrazin - 2-yl)- 2-methylphenyl)- 4,5,6,7-tetrahydrobenzo[b]thiophene-2-
carboxamide], a potent and selective BTK inhibitor, and characterize the relationship 
between inhibition of BTK phosphorylation (pBTK) and efficacy. These findings 
suggest a high degree of pBTK inhibition is required for maximal activity of the 
pathway on inflammatory arthritis in rats. 
 
CH3
N
+
N
NH
S
O
NH
N
N
CH3
CH3
O
O
CH3
 
Structure of GDC-0834 
 
5. Yan Lou et.al 42 reported  RN486, a Potent and Selective Bruton’s Tyrosine Kinase  
as a potent  inhibitor for the treatment of rheumatoid arthritis. Structure-based drug 
design was used to guide the optimization of a series of selective BTK inhibitors as 
potential treatments for Rheumatoid arthritis. introduction of a benzyl alcohol group 
and a fluorine substitution, each of which resulted in over 10-fold increase in activity. 
 
6. Akinleye et.al43 has reported  Ibrutinib, as an novel BTK inhibitors in clinical  
development Recently Bruton’s tyrosine kinase , a crucial terminal kinase enzyme in 
the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive 
target for therapeutic intervention in human malignancies and autoimmune disorders. 
Ibrutinib, a novel first-in-human BTK-inhibitor, has demonstrated clinical 
effectiveness and tolerability in early clinical trials and has progressed into phase III 
trials. 
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Structure of Ibrutinib 
 
7. Julie ADi Paolo et.al44 explained that BTK inhibition suppresses B-cell and myeloid 
cell–mediated arthritis.  In macrophages, BTK inhibition abolishes FcgRIII-induced 
TNFa, IL-1b and IL-6 production. Accordingly, in myeloid- and FcgR-dependent 
autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and 
ameliorates disease. These results provide new understanding of the function of BTK 
in both B- cell or myeloid cell–driven disease processes and provide a compelling 
rationale for targeting BTK in rheumatoid arthritis.  
 
8. Jian Liu et.al 45 synthesized few  8-Amino-imidazo[1,5-a]pyrazines as Reversible 
BTK Inhibitors for the Treatment of Rheumatoid Arthritis. Selectivity is achieved 
through specific interactions of the ligand with the kinase hinge and driven by 
aminopyridine hydrogen bondings with Ser538 and Asp539, and by hydrophobic 
interaction of trifluoropyridine in the back pocket. These interactions are evident in 
the X-ray crystal structure of the lead compounds 1 and 3 in the complex with the 
BTK enzyme.   
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The review on following works provided ideas for synthesis of the Imidazole 
chemical entities as Anti-arthritic agents 
9. Anti -inflammatory and analgesic activity 
Puratchikody A et.al
46
 have synthesized certain 2-substituted-4, 5-diphenyl-1H-
imidazoles and evaluated the anti-inflammatory activity based on Carrageenan-
induced paw edema method. This 2-substituted-4, 5-diphenyl-1H-imidazoles 
compound shows maximum activity when and also compared with indomethacin 
which was used as reference drug.  
N
N
O
 
2-substituted-4, 5-diphenyl-1H-imidazoles 
10. Debus et.al (1858)47 synthesized  some imidazolyl derivatives by using glyoxal and 
formaldehyde in ammonia. This synthesis, while producing relatively low yields, is 
still used for creating C substituted Imidazoles 
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11. Radiszewski Synthesis 
E.Lunt et.al
48
 reported the condensation of a dicarbonyl compound, benzil and α- 
keto aldehyde or benzaldehyde in the presence of ammonia, to yield 2, 4, 5 
triphenylimidazole. 
O
O
+ NH3 +
HO
N
H
N
  
12. Wahyuningrum et.al (2007)49  synthesized certain 4,5-substituted imidazole 
derivatives utilizing microwave assisted organic synthesis (MAOS) method, by 
reacting with suitable diketone and some aldehyde or ketone, in order to investigate 
their corrosion inhibition mechanism on carbon steel surface. 
O
R
1
O
R
1
+
O
R
2
N
H
N
+ 20 ml NH4OAC
 in 10 ml HOAC
Microvawe irradiation
 at 700 w
 
 
13. Kavitha C.S et.al50 has synthesized a series of 2-methylaminibenzimidazole 
derivatives   and all the newly synthesized compounds were screened for analgesic 
and anti-inflammatory activities.  
    
N
N NH Cl
Br
 
     2-methylaminibenzimidazole derivatives 
This compound shows analgesic activity and  also compared with standard nimusulide 
drug. 
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The review on following works related to  evaluation of anti-rheumatoid arthritic 
activity 
 
16. Caroline Charpin et.al 51 identified new autoantibodies associated with Rheumatoid 
Arthritis disease duration less than one year. These autoantibodies could be used as 
diagnosis markers in RA patients. 
 
17. Shruthi SD et.al 52 performed In-vivo, In-vitro and in silico anti-arthritic activity of a 
phytoconstituent, ellagic acid (EA) isolated from the leaves of K. Reticulata was  
isolated. The compound EA showed anti-arthritic activity which was found to be 
significant to that of the standard drugs aspirin and supports the traditional use of 
plant for treatment of rheumatism.  
 
18. A E van Ede et.al 53 studied purine metabolism during treatment with methotrexate 
(MTX) in patients with rheumatoid arthritis (RA) and also discussed the relation of 
purine metabolism with efficacy and toxicity of MTX treatment. 
 
19. Lars Klareskog et.al54 explained adaptive immunity in rheumatoid arthritis: 
anticitrulline and other antibodies in the pathogenesis of rheumatoid arthritis. Several 
different triggering mechanisms are involved in forming an antibody repertoire that 
evolves before the onset of clinical disease, and where antibodies with different 
specificities may interact directly or indirectly with target organs in causing different 
arthritis-associated symptoms. The increasing understanding of the role of adaptive 
and specific immunity in RA creates opportunities for a new generation of 
interventions. 
 
20. Victoria Kell and Mark Genovese 55 discovered a novel small molecule therapies 
which interrupt intracellular signalling through kinase inhibition. By interrupting one 
or more kinases it is possible to modulate the function of cellular structures such as 
surface receptors, signalling proteins and transcription of nuclear proteins and thus 
influence the behaviour of the cell types targeted. With these advances comes the 
significant potential to develop highly effective orally bioavailable therapeutics. 
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21. Mohammed Munawar Hossain et.al 56 performed an investigation of in vitro anti-
arthritic and membrane stabilizing activity of ethanol extracts of three Bangladeshi 
plants. Inhibition and proteinase actions were evaluated to assess the anti-arthritic 
effect of the selected plant extracts. Membrane stabilizing activity of extract were 
assessed by using hypotonic solution and heat-induced method. In highest 
concentration of Rhaphidophora glauca, Phrynium imbricatum, Steudnera 
colocasiifolia, showed significant antiarthritic activity (53.16%, 69.62%, 62.03%) 
and membrane stabilizing activity (49.05%, 71.9%, 60.22%) compared with 
Diclofenac-Na. 
 
22.  K. Sujatha et.al 57 performed the assessment of In-vitro anti-arthritic activtiy of 
Achyranthes Aspera linn. The ethanolic extract of Achyranthes aspera linn was 
investigated for its anti- inflammatory activity by using protein inhibition assay 
method. The seven concentration of the extract and diclofenac sodium (10, 50,100, 
200, 400,800, 1000 μg/ml) were used in this study as standard drug. The extract at 
the dose of 800 and 1000 μg /ml showed potent action on comparison with the 
standard diclofenac sodium. 
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IV. AIM AND OBJECTIVE OF WORK 
AIM 
The Main aim of this study is to identify, design, synthesize certain newer substituted 
imidazolyl derivatives as potent anti-rheumatoid arthritic agents with good predicted 
capability to inhibit the BTK involving Computational drug designing methods 
OBJECTIVE OF WORK 
 The plan of work includes the following steps, 
 Selection of target responsible for producing rheumatoid arthritis from the 
literature review which is carried out as part of the current research. 
 Identification of common Pharmacophoric features responsible for inhibiting 
Bruton’s Tyrosine Kinase. 
 Designing a series of leads that selectively modulate the activities of Bruton’s 
Tyrosine Kinase for exhibiting anti-rheumatoid arthritic activity. 
 The binding mechanism of BTK receptor and newly designed leads have to be 
studied using molecular docking with GLIDE 10.2 (PDB ID: 5fbn). 
  Optimisation of designed leads based on the Lipinski rule of five, ADMET 
properties using Molinspiration and Osiris software 
 Synthesis of certain optimized leads based on the synthetic feasibility. 
 Characterization of chemical nature of the synthesized compounds by   IR, 1H 
NMR, 
13
C NMR and GC-MS analysis. 
 Docking studies of all the synthesized compounds using GLIDE 10.2 and Argus 
Lab 4.0 
 Evaluation of all the synthesized compounds by performing In-vitro anti-arthritic 
activity -Protein inhibition assay method. 
    In-vivo Pharmacological screening  studies of   the synthesized compounds  
i) Evaluation of acute oral toxicity studies. 
ii) Evaluation of Anti- Rheumatoid Arthritic activity.  
V. EXPERIMENTAL WORK 
Overall experimental flow chart is depicted below, 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Identification and selection of Target Enzyme 
Q-Site finder 
Pharmacophore  Model 
Identification 
Generation of library of newer Lead 
(30-40) Molecules 
Finding an  active site  
of selected  target 
Lead Optimization 
 
Molecular Docking studies  
 
Drug likeliness prediction  
(Lipinski rule 
of five, Osiris) 
 
GLIDE 10.2 
Synthesis  of Selected ligand   
Characterization of Synthesized 
Compounds 
MP,TLC, IR, 
1
H & 
13
C 
NMR, GC-MS 
Docking studies of synthesized compounds 
GLIDE10.2 
and Argus 
lab 4.1 
In-vitro & In-vivo evaluation of Rheumatoid Arthritic activity for synthesized  
compounds 
Fig No7: Flow chart 
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V.A.DRUG DESIGN 
 MATERIALS AND METHODS 
1. SELECTION OF TARGET ENZYME 
Protein Data Bank (PDB) is a crystallographic database for three dimensional structural 
data of large biological molecules such as proteins, Nucleic acid and Complex 
assemblies. The targets creating the greatest enthusiasm at this time for the treatment of 
Rheumatoid Arthritis and Inflammatory diseases include Janus-associated kinase (JAK), 
spleen tyrosine kinase (SYK), phosphodiesterase-4, Bruton’s tyrosine kinase (BTK) and 
phosphatidylinositol-3 kinase. Ultimately human trials will help to understand the 
potential risks and benefits of these novel approaches across a number of diseases
58,59
.   
Using Q-site finder software tool, some of the recent and efficient PDB enzyme targets 
with low resolution were selected and further evaluated by its Resolution value, R Free, 
R value and optimised crystal ligand interaction details. Some of the selected receptors 
are listed below from which the highlighted best PDB target was used in this study 
Table 1: List of target for Rheumatoid Arthritis 
ABL ACK CSK FAK FES FRK JAK 
SRC-
A 
SRC-
B 
TEC SYK 
 
ABL1 
 
ARG 
 
ACK1 
 
TNK1 
 
CSK 
 
MATK 
 
FAK 
 
PYK2 
 
FER 
 
FES 
 
 
BRK 
 
FRK 
 
SRMS 
 
JAK1 
 
JAK2 
 
JAK3 
 
TYK2 
 
FGR 
 
FYN 
 
SRC 
 
YES1 
 
 
 
BLK 
 
HCK 
 
LCK 
 
LYN 
 
 
 
BMX 
 
BTK 
 
ITK 
 
TEC 
 
TXK 
 
SYK 
 
ZAP 
70 
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 Bruton’s tyrosine kinase (BTK) is a cytoplasmic, non-receptor, tyrosine kinase 
which is expressed in most of the hematopoitic cells and plays an important role in the 
development, differentiation and proliferation of B-lineage cells, thus making BTK an 
efficient therapeutic target for the treatment of rheumatoid arthritis. Recent researchers 
suggested BTK as a therapeutic potential target to treat Rheumatoid Arthritis and Cancers
 
which prompted us to select the BTK as the protein target in this study
60
.      
 
Fig.No.8: 3D Structure of BTK 
 
  Crystal Structure : BTK 
  PDB code  : 5FBN 
  Method  : X-RAY DIFFRACTION 
  Resolution  : 1.8 Å 
  R-Value Free  : 0.226 
  R-Value Work : 0.179  
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Active site of selected PDB 
 The active site of selected protein was identified by using Q-site finder software 
in which ligand mapping is used to show the active site of the existed co-crystal ligand 
.The active site of the selected target ezyme –BTK are identified as follows 
 
5WE 702 (C) : Gln 459, Ser 453, Leu 460, Tyr 461, Asp 426, Gly 462, Ile 397,  
Trp 421, Tyr 425, Val 427. 
5WF 701 (C) : Asn 484, Cys 481, Gly 409, Gly 480, Leu 408, Thr 410, Gly 411, 
Thr 476, Ala 478, Val 458, Glu 475, Met 477, Leu 528, Ala 428, Val 
416, Leu 460, Met 450, Asp 539, Leu 542, Phe 442, Phe 540, Met 
449, Val 463, Ile 472, Lys 430. 
5WE 703 (D) : Gln 459, Ser 453, Trp 421, Leu 460, Ile 397, Ser 394, Gly 462, Val 
427, Tyr 461, Met 450, Asp 426, Trp 421, Tyr 425.  
5WE 704 (D) : Tyr 631, Arg 618, Glu 624. 
5WE 705 (D) : Glu 624, Arg 618, Tyr 627, Thr 628, Tyr 631. 
5WF 702 (D) : Asn 484, Cys 481, Gly 480, Leu 408, Thr 410, Thr 474, Gly 411, Leu 
528, Glu 475, Val 416, Ala 428, Asp 539, Ala 446, Leu 542, Lys 430, 
Ser 538, Leu 460, Leu 542, Ser 538, Ala 446, Leu 542, Met 449,  
Phe 540, Val 463.   
2. PHARMACOPHORE MODELING61 
a) Pharmacophore identification 
 A Pharmacophore is defined as “a set of structural features in a molecule that is 
recognized at a receptor site and is responsible for that molecule’s biological activity”. 
When reviewing the efficient journals and research articles, (Rohit Bavi et.al  reported 
the 3D QSAR Modeling of Bruton’s tyrosine kinase in 2016) Pharmacophore model 
consisting of  HBD, HBAL, HYP features was identified  as the best model for 
designing BTK Inhibitors.  
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 This pharmacophore model revealed that five chemical features  consisting of one 
hydrogen bond acceptor lipid (HBAL), one hydrogen bond donor (HBD), three 
hydrophobic (HYP) features could effectively map all the chemical features. Hence, the 
above best hypothesis Hypo 1 was used as 3d structural query to screen the chemical 
databases for retrieving new potent BTK inhibitors.   
 
 
Fig.No.9: Chemical features of the best Pharmacophore 'Hypo 1' with its distance 
constraints.'Hypo 1' consists of one hydrogen bond acceptor lipid (HBAL: Green),  
one hydrogen bond donor (HBD: Magenta), three hydrophobic (HYP: Cyan) features.
 
 
Examples of HBAL and HBD Molecular Fragments 
     
  Fig.No.10: HBAL and HBD Molecular Fragments 
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b) Database screening 
 Scaffold hopping, or chemo type switching, is a technology that modifies the 
chemical scaffold of a bioactive compound retaining the activity and key interaction 
points, or the interacting molecular fragments of the parent compound. 
 Based on the above quoted literature facts in designing potent BTK inhibitors, the 
target screening library was designed by using  molecular fragments from a relatively 
narrow and low molecular weight range (350-5000D), selected diversity at both the 
putative “scaffold” core. The analogue library was generated by modifying the respective 
functional groups with sterically and conformationally allowed substituents using the 
reagent database and a combinatorial design model.  
Table.No.2: Molecular fragments used in construction of library 
HBD  HBA  Linker Hydrophobic tail  
 
Imidazole, 
Benzimidazole, 
Aminothiazole, 
Phenolic-OH, 
Aniline, Alkyl 
amines, 
Hydrazines, 
Morpholine 
 
C=O  of  aliphatic 
and aromatic 
amides , 
C=O of aromatic 
ketones, 
 
 
 
 
Phenyl, 
Methyl, 
Ethyl, 
Phenoxy, 
 
 
Phenyl, 
Diazole, 
Pyridine 
Triazole, 
Quinaxoline, 
dimethyl benzene, 
 
Construction of a Large Virtual Scaffold Library 
                A library consisting of nearly new 30-40 lead molecules as potent BTK 
inhibitors was generated based on the knowledge of binding interaction of Ligand with 
the protein and also the common features necessary for the biological activity of 
molecule .The Hypo1 model (one hydrogen bond acceptor lipid (HBAL), one hydrogen 
bond donor (HBD), three hydrophobic (HYP) features) was used to screen knowledge 
database and   a virtual scaffold library consisting of newly designed 33 molecules has 
been constructed have been shown in below, 
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Lig 27                                                 lig 28                                                    lig 29 
  
 
            
 
                 
 
Lig 30                                                  lig 31                                                             lig32
  
 
   
 
    lig 33     
 
Fig.No.11:  Virtual scaffold library of newly designed leads as BTK inhibitors 
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3. LEAD OPTIMIZATION 
All the designed ligands (1-33) were optimized by subjecting to Docking studies, 
ADMET properties, Lipinski’s rule of five, Novelty prediction and Toxicity prediction to 
refine further.  
 
A. DOCKING STUDIES OF DESIGNED LEADS 
a) Preparation of protein target structure 
 The crystal structure of BTK inhibitor (PBD ID: 5FBN, Resolution 1.8 Å) was 
downloaded from the Protein Data Bank (www.rcsb.org) and employed for Glide 10.2 
docking studies. For GLIDE (Schrodinger) calculations, BTK Target enzyme was 
imported to Maestro (Schrodinger), the co-crystalized ligands were identified and 
removed from the structure and the protein was minimized using the protein preparation 
wizard (shipping by Schrodinger) by applying an OPLS force field. The refinement 
procedure is recommended by Schrodinger because Glide uses the full OPLS force field 
at an intermediate docking stage and is claimed to be more sensitive to geometrical 
details than other docking tools. Water molecule were removed and the hydrogen atom 
were added to the structure. The most likely position of hydroxyl and H atoms were 
added to the structure. Minimization were performed until the average root mean square 
deviation of the Non hydrogen atoms reached 0.3 Å. 
 
b) Ligand preparation 
 3D structure of BTK ligands were built and adjusted for bond order using 
Maestro 10.2 (Schrodinder suite). Geometry minimization were performed on all ligand 
using the OPLS force field and the Truncated Newton Conjugate Gradient (TNCG) 
minimization algoritham. Optimization of ligand conformations were converged to a 
gradient RMSD below 0.05 KJ/Mol or continued to a maximum of 1000 interaction, at 
which point there were negligible changes in RMSD gradients. 
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The structures supplies to docking tool must meet the following condition, 
1. They must be three- dimentional (3D). 
2. They must have realistic bond lengths and bond angles. 
3. They must each consist of a single molecule that has no covalent bonds to the 
receptor, with no accompanying fragments, such as counter ions and solvent 
molecules. 
4. They must have all their hydrogens (field valences). 
5. They must have an appropriate protonation state for physiological pH value 
around 7. 
 
c) Docking studies using GLIDE 10.2 
 Docking was performed on BTK, twenty distinct poses of each ligand in the 
active site of BTK were generated. The binding pocket of  BTK is made up of key 
residues Thr 410, Asp 539, Phe 540. The ligand IPAA, ISA, IPABA, IHA and IAA 
were found to have very high fitness score. It was also observed that the hydrogen bond 
and pi-pi static interactions between the target and the ligands. 
 
B. DRUG LIKENESS SCREENING 
 The properties which can differentiate drugs other chemicals can be considered as 
drug like properties. Drug likeness is qualitative concept used in drug design for how 
druglike a substances is to be an effective drug. Drug likeliness properties was performed 
for all the newly designed BTK inhibitors by using different  online softwares like 
Lipinski’s rule of five, Osiris online software, Molinspiration.. 
 
a) Lipinski’s rule of five 
 Lipinski’s rule of five is a rule of thumb to evaluate drug likeness, or to determine 
if a chemical compound with a certain pharmacological or biological activity has 
properties that would make it a likely orally active drug in humans. The rule was 
formulated by Christopher A. Lipinski in 1997, based on the observation that most 
medication drugs are relatively small and lipophilic molecules.  
 The modification of the molecular structure often leads to drugs with higher 
molecular weight, more rings, more rotatable bonds and higher lipophilicity. The rule is 
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called “Rule of 5”, because the border values are 5, 500, 2*5. The rule of five was 
calculated using a software tool called Molinspiration online database. 
 
Lipinski’s rule says that, in general, an orally active drug has no more than one violation 
of the following criteria, 
 Log P value should be less than 5 
 Hydrogen bond donor less than 5  
 Hydrogen bond acceptor less than 10  
 Molecular weight under  500 Daltons and  
 Not more than 10 rotatable bonds.  
 
b)  ADMET properties 
The ADMET provides components that calculate predicted absorption, distribution, 
metabolism, excretion, and toxicity (ADMET) properties for ligand. A drug substances 
must be characterized by optimal solubility to both water and fat. The model compound 
for cellular membrane is octanol, so the logarithm of the octanol/water partition co 
efficient, known as log Po/w, is used to estimate the solubility. Solubility in water can be 
estimated from the number of hydrogen bond donors vs the alkyl side chains in the 
molecule. Too many hydrogen bond donors, on the other hand, leads to low fat 
solubility, so the drug cannot penetrate the cell wall.  
 During ADMET investigation the ligands were checked for low blood brain barrier 
(BBB), optimal solubility, good absorption. The toxicological properties like 
Teratogenicity, Mutagenicity, Irritant effect and Reproductive effect of designed ligands 
were predicted using Osiris online software. Prediction results are evaluated and color 
coded. Unfavorable properties or those with high risk of side effect like mutagenicity or 
poor intestinal absorption in Red, Green whose indicate Drug-conform. 
 
 
 
 
 
 
EXPERIMENTAL WORK 
 
 
 
35 
RESULTS AND DISSCUSSIONS 
A. DOCKING STUDIES 
  Docking studies was performed on all the newly designed 33 BTK inhibitors 
retrieved from virtual screening using Glide 10.2. Results of predicted activity of  all the 
designed ligands with fitness score are tabulated below 
 
Table.No.3: List of docking score for designed ligands 
S. 
No 
Ligand Docking score Using Glide 10.2 
1 Lig 1 -7.864 
2 Lig 2 -9.264 
3 Lig 3 -7.159 
4 Lig 4 -8.141 
5 Lig 5 -7.426 
6 Lig 6 -6.808 
7 Lig 7 -7.050 
8 Lig 8 -7.567 
9 Lig 9 -6.437 
10 Lig 10 -9.684 
11 Lig 11 -7.267 
12 Lig 12 -7.970 
13 Lig 13 -7.770 
14 Lig 14 -7.632 
15 Lig 15 -6.460 
16 Lig 16 -6.800 
17 Lig 17 -4.731 
18 Lig 18 -6.351 
19 Lig 19 -5.651 
20 Lig 20 -5.987 
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S. 
No 
Ligand Docking score Using Glide 10.2 
21 Lig 21 -6.262 
22 Lig 22 -4.279 
23 Lig 23 -5.887 
24 Lig 24 -7.828 
25 Lig 25 -7.229 
26 Lig 26 -4.807 
27 Lig 27 -6.134 
28 Lig 28 -5.670 
29 Lig 29 -5.000 
30 Lig 30 -5.034 
31 Lig 31 -6.422 
32 Lig 32 -7.891 
33 Lig 33 -6.943 
 
B. DRUG LIKELINESS PROPERTIES 
 When all the 33 newly designed  ligands were  subjected to drug likeness 
prediction studies all were  found to exhibit the drug likeness properties.  But based on 
the synthetic feasibility only Ligand (6), Ligand (9), Ligand (14), Ligand (13), 
Ligand(12) were selected as lead for synthesis as potent BTK inhibitor and hence the 
results of selected ligands alone were discussed  below, 
 
a) Lipinski’s rule of five 
 The Lipinski’s rule of five was performed by using Lipinski’s rule of five 
molecular properties calculator online software. All the selected ligands Ligand 6, 
Ligand 9, Ligand 14, Ligand 13, Ligand 12 were found to pass the Lipinski rule of five 
and the results were tabulated below, 
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Table.No.4: Lipinski rule of five reports for the selected ligands 
S. 
No 
Ligands 
Molecular 
Mass 
(Dalton) 
 
logP(<5) 
Hydrogen 
bond 
donor(<5) 
Hydrogen 
bond 
acceptor(<10) 
Molar 
Refractivity(40-
130) 
1 
 
Ligand 6 
364.00 3.239840 3 4 108.616570 
2 
 
Ligand 9 
365.00 3.362879 2 4 105.868965 
3 
 
Ligand 
14 
379.00 3.422479 1 4 110.375664 
4 
 
Ligand 
13 
404.00 3.254679 1 5 117.703156 
5 
 
Ligand 
12 
364.00 3.239840 3 4 108.616570 
 
Table.No.5:  Molecular properties of selected ligands 
S. 
No 
Ligands No of atoms 
No of rotatable 
bonds 
TPSA Violation 
1 Ligand 6 28 5 83.80 0 
2 Ligand 9 28 5 78.01 0 
3 Ligand 14 29 7 67.02 0 
4 Ligand 13 28 5 83.80 0 
5 Ligand 12 31 7 86.88 0 
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b) ADMET properties 
The ADMET results of the selected ligands were depicted in the following images, 
Ligand 6 
Biological activity 
 
 
Physiochemical Properties 
 
  
Toxicity profile 
 
Fig.No.12: Biological activity, Physiochemical Properties and Toxicity profile 
images for Ligand 6 
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Ligand 9 
Biological activity 
 
 
Physiochemical Properties 
 
      
Toxicity profile 
 
Fig.No.13: Biological activity, Physiochemical Properties and Toxicity profile 
images for Ligand 9 
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Ligand 14 
Biological activity 
 
 
Physiochemical Properties 
 
 
Toxicity profile 
 
 
Fig.No.14: Biological activity, Physiochemical Properties and Toxicity profile 
images for Ligand 11 
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Ligand 13 
Biological activity 
 
 
Physiochemical Properties 
 
 
Toxicity profile 
 
 
Fig.No.15: Biological activity, Physiochemical Properties and Toxicity profile 
images for Ligand 13 
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Ligand 12 
Biological activity 
 
 
 
Physiochemical Properties 
 
 
Toxicity profile 
 
Fig.No.16: Biological activity, Physiochemical Properties and Toxicity profile 
images for Ligand 12 
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Thus the proposed ligands for synthesis Ligand (6), Ligand (9), Ligand (14), 
Ligand (13), Ligand (12) have satisfied all the above filtering method of good predictive 
activity with good docking scores and also drug likeness properties confirming that these 
molecules are accepted to be orally bioavailable.  
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V. B. SYNTHESIS AND CHARACTERIZATION 
 
1. MATERIALS AND METHODS 
SYNTHESIS 
          Reactants and solvents used were of analytical grade .Purification of the product 
were done by Thin layer chromatographic technique. TLC was performed using 
Aluminum plates pre-coated with Silica gel 60F 254 (E-Merck); detected using UV light 
chamber and Iodine chamber. Melting points were taken in an open capillary tubes and 
are present uncorrected. 
 
CHEMICAL USED FOR SYNTHESIS 
ANTHRANILIC ACID 
 
NH2
OH
O  
 
 
 Molecular formula   :   C7H7NO2 
 Molecular weight  :  137.14 g/mol. 
Description    :  white solid 
Melting point   :   144-148 °C 
Boiling point    :    200 °C 
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HIPPURIC ACID 
 
NH
OH
O
O
 
 
Molecular formula   :  C9H9NO3 
Molecular weight   :  179.17 g/mol. 
Description    :  White crystals 
Melting point   :  187-191 °C 
Boiling point    :  240 °C 
 
 
PHENOXY ACETIC ACID 
 
O
OH
O  
 
Molecular formula   :  C8H8O3 
Molecular weight   :  152.15 g/mol. 
Description    :   White needle crystal 
Melting point   :  98-100 °C 
Boiling point    :  285 °C 
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SALICYLIC ACID 
 
OH
OH
O
 
 
Molecular formula   :  C7H6O3 
Molecular weight  :  138.12 g/mol. 
Description    :  white to off-white crystalline powder 
Melting point   :  159 °C 
Boiling point    :  211 °C 
 
 
PARA AMINO BENZOIC ACID 
 
NH2
OH
O
 
 
 
Molecular formula   :  C7H7O2N 
Molecular weight   :  137.14 g/mol. 
Description    :  White Crystalline powder 
Melting point   :  187 °C 
Boiling point   :  340 °C 
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CHLORO ACETALDEHYDE 
 
H
O
Cl 
 
Molecular formula   :  C2H3ClO 
Molecular weight   :  78.5 g/mol. 
Description    : Clear colorless liquid with pungent odour 
Melting point   :  -28 to 23°C 
Boiling point    :  80-100 °C 
 
 
BENZIL 
 
O
O
 
 
Molecular formula   :  C14H10O2 
Molecular weight   :  210.23 g/mol. 
Description    : Yellow solid 
Melting point   :  94-95 °C 
Boiling point    :  346 °C 
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INSTRUMENTS USED FOR CHARACTERIZATION 
The synthesized compounds were characterized by Infra-red spectra (IR), Nuclear 
Magnetic Resonance (
1
H NMR, 
13
C NMR), GC-MASS Spectra.  
Melting point 
The melting point were recorded on a Melting point apparatus by using a capillary tube. 
IR spectra 
 IR Spectra was recorded using KBr pellets in then range 4000-500cm-1 on a   
ABB Bomen FT-IR spectrophotometer using KBr pellets 
1
H NMR spectra 
 Proton NMR (500MHz) Spectra was recorded were recorded deutrated methanol 
as solvent on BRUKER Advance III 500 NMR Spectrophotometer. Chemical 
shifts are shifted in parts per million downfield with reference to tetramethyl 
silane (TMS) as internal standard.
      
 
13
C NMR spectra 
 13C-NMR was recorded using solvent CDCl3 on BRUKER Advance III 400 NMR 
Spectrophotometer. 
GC-MS spectra 
         GC-MS spectra were recorded using combined gas chromatography and mass 
spectroscopy on Perkin Elmer Clarus 680 GC-MS spectrometer. 
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   CHEMICAL SYNTHESIS 
                     
H
O
Cl 
                             
 
 
 
 
                       
                                                                      
 
 
 
 
 
 
    
 
 
                                                            
R  =  2-NH2,  4-NH2,  2-OH 
Fig.No.17: Scheme 
 
+ 
4-5 hr Reflux 
2-(chloromethyl)-4,5- 
diphenyl-1H-imiazole 
Benzil Chloro 
acetaldehyde 
-2CH3COOH 
-2H
2
O 
NH
3
 
 K
2
CO
3
 
STEP II 
-HCl 
1-(4,5-diphenyl-1H-imidazol-2-yl)methanamine
R 
STEP III 
R 
N-[(4,5-diphenyl-1H-imidazol-2-yl)methyl]benzamide
STEP I 
Ammonium acetate 
N-[(4,5-diphenyl-1H-imidazol-2-yl)methyl]benzamide
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Procedure 
STEP I: Synthesis of 2-substituted 4, 5-diphenyl imidazole 2-(chloromethyl)-4, 5-
diphenyl-1H-imidazol (Radiswiski synthesis from benzil) 
62
. 
 Benzil (25 mmol, 5.25g), aldehyde (25 mmol) and ammonium acetate (10g) were 
dissolved in glacial acetic acid and then refluxed for 3-5 hrs. After refluxing, the reaction 
mixture was left overnight and filtered to remove any impurities that may be present. 
Water (300 ml) was then added to the filtrate and the precipitate formed was collected. 
The filtrate was neutralized with ammonium hydroxide and then the second crop of the 
solid was collected. The two crops of the solid were combined, dried and recrystallized 
from ethanol. The purity of product was established by single spot on TLC. The 
percentage yield was found to be 80 % w/w. 
 
STEP II: 2-(chloromethyl)-4, 5-diphenyl-1H-imidazole from Step I product
63
. 
 2-(chloromethyl)-4, 5-diphenyl-1H-imidazol (0.2 mol), was prepared by reported 
method. Ammonia (0.1 mol) in acetone-water mixture was added. K2CO3 (0.1mol, 
14.0g) was added as an acid acceptor. The resulting mixture was refluxed for 3 hrs with 
occasional shaking. The resulting suspension was poured into ice cold water (500 ml) 
and then filtered. The solid product was collected and dried to give 2-(chloromethyl)-4, 
5-diphenyl-1H-imidazole. The purity of product was established by single spot on TLC. 
The percentage yield was found to be 80 % w/w. 
 
STEP III:  N-[(4, 5-diphenyl-1H-imidazol-2-yl)methyl]-2-benzamide from step II 
process
 64
. 
 Aromatic acid (0.029 mol) and 2-(chloromethyl)-4, 5-diphenyl-1H-imidazol 
(0.026 mol), were dissolved in dry pyridine (0.25 mol) and refluxed for 8 hrs. Then the 
solution was cooled and poured in water. The separated mass was filtered, washed with 
water and dried. The products were recrystallized with ethanol. The purity of product 
was established by single spot on TLC. The percentage yield was found to be 80 % w/w. 
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2. RESULT AND DISSCUSSION 
 The  imidazolyl derivatives were prepared in the same manner with different 
substituted Aromatic acids such as Para amino benzoic acid, Anthranilic acid, Hippuric 
acid, Phenoxy acetic acid, Salicylic acid.  
List of the synthesized compounds structure and their IUPAC name is tabulated below, 
Table.No.6: List of compounds synthesized 
Drug code IUPAC name Structure of synthesized compounds 
 
 
 
IPAA 
N-[(4,5-diphenyl-
1H-imidazol-2-
yl)methyl]-2-
phenoxyacetamide 
 
 
 
 
 
ISA 
N-[(4,5-diphenyl-
1H-imidazol-2-
yl)methyl]-2-
hydroxybenzamide 
 
 
 
 
IPABA 
4-amino-N-[(4,5-
diphenyl-1H-
imidazol-2-
yl)methyl]benzamide 
 
 
 
 
 
 
IHA 
 
N-[(4,5-diphenyl-
1H-imidazol-2-
yl)methyl]-2-
benzamide 
 
 
 
IAA 
2-amino-N-[(4,5-
diphenyl-1H-
imidazol-2-
yl)methyl]benzamide 
 
 
 
 
N
H
N
NH
O
NH2
N
H
N
NH
O
O
N
H
N
NH
O
OH
N
H
N
NH
O
NH2
N
H
N
NH
O
NH
O
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Physiochemical Properties of Synthesized Compounds 
IPAA 
 
          Fig.No.18: N-[(4, 5-diphenyl-1H-imidazol-2-yl) methyl]-2-phenoxyacetamide 
 
Molecular Formula  : C24 H21 N3 O2 
Molecular Weight  : 384.44244 
Composition   : C (75.18 %)  H (5.52%) N (10.96 %) O (8.35%) 
Molar Refractivity  : 112.01 + 0.3 cm
3
 
Molar Volume  : 315.2 + 3.0 cm
3
 
Refractive Index (n)  : 1.629 + 0.02 
Density   : 1.216 + 0.06 g /cm
3
 
Surface Tension (γ)  : 52.6 + 3.0 dyne/cm 
Dielectric Constant  : N/A 
Polarisability ( )  : 44.40 + 0.5 cm3 
M+    : 383. 162828 Da 
M-    : 383.163926 Da 
[M+H]+   : 384.170635 Da 
[M+H]-   : 384.171751 Da 
[M-H]+   : 382.155003 Da 
[M-H]-   : 382.1561 Da 
Melting Point   : 45-70
o
C 
Rf Value   : 0.83 
Yield    : 58.43 % w/w 
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ISA 
 
   Fig.No.19: N-[(4, 5-diphenyl-1H-imidazol-2-yl) methyl]-2-hydroxybenzamide 
 
Molecular Formula  : C23 H19 N3 O2 
Molecular Weight  : 369.41586 
Composition   : C (74.78 %)  H (5.18%) N (11.37%) O (8.66%) 
Molar Refractivity  : 107.95 + 0.3 cm
3
 
Molar Volume  : 291.0 + 3.0 cm
3
 
Refractive Index (n)  : 1.664 + 0.02 
Density   : 1.249 + 0.06 g /cm
3
 
Surface Tension (γ)  : 59.4 + 3.0 dyne/cm 
Dielectric Constant  : N/A 
Polarisability ( )  : 42.79 + 0.5 cm3 
M+    : 369. 147178 Da 
M-    : 369.148275 Da 
[M+H]+   : 370.155003 Da 
[M+H]-   : 370.1561 Da 
[M-H]+   : 368.139353 Da 
[M-H]-   : 368.14045 Da 
Melting Point   : 55-75
o
C 
Rf Value   : 0.83 
Yield    : 59.24 % w/w 
       
EXPERIMENTAL WORK 
 
54 
 
IPABA 
 
 Fig.No.20: 4-amino-N-[(4, 5-diphenyl-1H-imidazol-2-yl) methyl] benzamide 
 
Molecular Formula  : C23 H20 N4 O 
Molecular Weight  : 368.4311 
Composition   : C (74.98 %)  H (5.47%) N (15.21%) O (4.34%) 
Molar Refractivity  : 110.30 + 0.3 cm
3
 
Molar Volume  : 294.8 + 3.0 cm
3
 
Refractive Index  : 1.671 + 0.02 
Density   : 1.249 + 0.06 g /cm
3
 
Surface Tension (γ)  : 59.4 + 3.0 dyne/cm 
Dielectric Constant  : N/A 
Polarisability ( )  : 43.72 + 0.5 cm3 
M+    : 368. 163163 Da 
M-    : 368.16426 Da 
[M+H]+   : 369. 170988 Da 
[M+H]-   : 369.172085 Da 
[M-H]+   : 369.155338 Da 
[M-H]-   : 367. 156435 Da 
Melting Point   : 50-80
o
C 
Rf Value   : 0.54 
Yield    : 78.3284 % w/w 
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IHA 
 
 Fig.No.21: N-[(4, 5-diphenyl-1H-imidazol-2-yl) methyl]-2-benzamide 
 
Molecular Formula  : C25 H22 N4 O2 
Molecular Weight  : 410.46778 
Composition   : C (73.15 %)  H (5.40%) N (13.65 %) O (7.80%) 
Molar Refractivity  : 118.96 + 0.3 cm
3
 
Molar Volume  : 331.5 + 3.0 cm
3
 
Refractive Index (n)  : 1.636 + 0.02 
Density   : 1.238 + 0.06 g /cm
3
 
Surface Tension (γ)  : 55.6 + 3.0 dyne/cm 
Dielectric Constant  : N/A 
Polarisability ( )  : 47.16 + 0.5 cm3 
M+    : 410. 173727 Da 
M-    : 410.174825 Da 
[M+H]+   : 411.181552 Da 
[M+H]-   : 411.18265 Da 
[M-H]+   : 409.165902 Da 
[M-H]-   : 409.167 Da 
Melting Point   : 70-85
o
C 
Rf Value   : 0.80 
Yield    : 57.31 % w/w 
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IAA 
 
        Fig.No.22: 2-amino-N-[(4, 5-diphenyl-1H-imidazol-2-yl)methyl] benzamide 
 
Molecular Formula  : C23 H20 N4 O 
Molecular Weight  : 368.4311 
Composition   : C (74.98 %)  H (5.47%) N (15.21%) O (4.34%) 
Molar Refractivity  : 110.30 + 0.3 cm
3
 
Molar Volume  : 294.8 + 3.0 cm
3
 
Refractive Index  : 1.671 + 0.02 
Density   : 1.249 + 0.06 g /cm
3
 
Surface Tension (γ)  : 59.4 + 3.0 dyne/cm 
Dielectric Constant  : N/A 
Polarisability ( )  : 43.72 + 0.5 cm3 
M+    : 368. 163163 Da 
M-    : 368.16426 Da 
[M+H]+   : 369. 170988 Da 
[M+H]-   : 369.172085 Da 
[M-H]+   : 369.155338 Da 
[M-H]-   : 367. 156435 Da 
Melting Point   : 60-85
o
C 
Rf Value   : 0.77 
Yield    : 57.36 % w/w 
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3. CHARACTERIZATION  
All the synthesized compounds IPAA, ISA, IPABA, IHA, IAA have been 
characterized by using different analytical techniques like IR, NMR, GC-MS and the 
results are given below, 
IR spectra of compound IPAA 
 
 
Table.No.7:  IR Spectral data of synthesized IPAA (KBr) 
S. No Wave Number (Cm
-1
) Functional Group 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
3733.91 
3409.90 
3055.02 
2923.44 
1674.09 
1596.94 
1481.22 
1442.65 
771.47 
694.22 
 
Amide NH str  
Hetero -Ar NH str 
Ar CH str 
Alkyl CHstr  
Amide C=O str  
Imidazole C=N str 
C-N str 
Phenoxy C-O str  
Ar CH bending  
Alkyl CH bending  
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IR spectra of compound ISA 
 
 
 
Table.No.8:  IR Spectral data of ISA (KBr) 
S. No Wave Number (Cm
-1
) Functional Group 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
3795.63 
3733.91 
3440.76 
2923.87 
2854.44 
1674.09 
1643.23 
1481.22 
1450.36 
1072.34 
763.76 
694.32 
Amide NH str  
Hetero Ar NH str 
Phenolic OH str 
Ar CH str 
Alkyl CH str 
Amide C=O str 
Imidazole C=N str 
C-N str 
Phenolic O-H bending  
C-C bending 
Ar CH bending 
Alkyl CH bending  
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IR spectra of compound IPABA 
 
 
 
Table.No.9:  IR Spectral data of IPABA (KBr) 
S. No Wave Number (Cm
-1
) Functional Group 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
3757.06 
3448.47 
2923.87 
2854.44 
1658.66 
1596.94 
1481.22 
1365.50 
1072.34 
763.73 
686.61 
Amide NH str  
Hetero Ar NH str 
Ar CH str 
Alkyl CH str 
Amide C=O str 
Imidazole C=N str 
C-N str 
Ar NH bending  
C-C bending  
Ar CH bending 
Alkyl CH bending 
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IR spectra of compound IHA 
 
 
 
Table.No.10:  IR Spectral data of IHA (KBr) 
S. No Wave Number (Cm
-1
) Functional Group 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
3749.34 
3487.04 
2923.87 
2854.44 
1650.95 
1550.65 
1458.08 
1164.92 
771.47 
694.32 
Amide NH str  
Hetero Ar NH str 
Ar CH str 
Alkyl CH str  
Amide C=O str 
Imidazole C=N str 
C-N str 
 C-C str 
Ar CH bending  
Alkyl CH bending 
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IR spectra of compound IAA 
 
 
 
Table.No.11:  IR Spectral data of IAA (KBr) 
S. No Wave Number (Cm
-1
) Functional Group 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
3733 
3494.76 
2923.87 
2854.44 
1674.09 
1604.66 
1481.22 
1373.22 
1072.34 
763.76 
636.81 
Amide NH str  
Hetero Ar NH str 
Ar CH str 
Alkyl CH str 
Amide C=O str 
Imidazole C=N str 
C-N str 
Ar NH bending  
C-C bending  
Ar CH bending  
Alkyl CH bending 
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1
H NMR spectra of compound IPAA  
 
 
 
Table.No.12: 
1
HNMR Spectral nature of IPAA 
S. 
No 
δ value Nature of peak Number of proton 
1 4 Multiplet 4 proton 
2 8 Doublet 2 proton 
3 7-9 Multiplet 15 proton 
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1
H NMR spectra of compound ISA 
 
 
 
 
Table.No.13: 
1
HNMR Spectral nature of ISA 
S. 
No 
δ value Nature of peak Number of proton 
1 8 Multiplet 7 proton 
2 7-9 Multiplet 15 proton 
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1
H NMR spectra of compound IPABA 
 
 
Table.No.14: 
1
HNMR Spectral nature of IPABA 
S. No δ value Nature of peak Number of proton 
1 8 Triplet 3 proton 
2 7-9 Multiplet 17 proton 
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1
H NMR spectra of compound IHA 
 
 
Table.No.15: 
1
HNMR Spectral nature of IHA 
S. 
No 
δ value Nature of peak Number of proton 
1 4.46 Triplet 3 proton 
2 8 Multiplet 3 proton 
3 7-9 Multiplet 16 proton 
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1
H NMR spectra of compound IAA 
 
 
 
Table.No.16: 
1
HNMR Spectral nature of IAA 
S. No δ value Nature of peak Number of proton 
1 8 Triplet 3 proton 
2 7-9 Multiplet 17 proton 
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13
C NMR spectra of compound IPAA 
 
 
 
Table.No.17: 
13
CNMR Spectral nature of IPAA 
S. No δ Value Functional carbon 
1 
2 
3 
4 
129.4 
133.1 
37.9 
169.0 
Imidazole C (3) 
Aromatic C (16) 
Alkyl C (2) 
Amide C (1) 
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13
C NMR spectra of compound ISA 
 
 
 
Table.No.18: 
13
CNMR Spectral nature of ISA 
 
S. No δ Value Functional carbon 
1 
2 
3 
4 
129.4 
133.1 
37.9 
169.0 
Imidazole C (3) 
Aromatic C (16) 
Alkyl C (1) 
Amide C (1) 
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13
C NMR spectra of compound IPABA 
 
                  
Table.No.19: 
13
CNMR Spectral nature of IPABA 
S. No δ Value Functional carbon 
1 
2 
3 
4 
129.4 
133.1 
37.9 
169.0 
Imidazole C (3) 
Aromatic C (16) 
Alkyl C (1) 
Amide C (1) 
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13
C NMR spectra of compound IHA
 
 
 
 
Table.No.20: 
13
CNMR Spectral nature of IHA 
S. No δ Value Functional carbon 
1 
2 
3 
4 
129.4 
133.1 
37.9 
169.0 
Imidazole C (3) 
Aromatic C (16) 
Alkyl C (2) 
Amide C (2) 
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13
C NMR spectra of compound IAA
 
 
Table.No.21: 
13
CNMR Spectral nature of IAA 
S. No δ Value Functional carbon 
1 
2 
3 
4 
129.4 
133.1 
37.9 
169.0 
Imidazole C (3) 
Aromatic C (16) 
Alkyl C (1) 
Amide C (1) 
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GC-MS Spectra of compound IPAA 
 
 
 Table.No.22: GC-MS Spectral nature of compound IPAA  
S. No Peak Molecular Weight 
1 M 384.2807 
2 M+1 385.3940 
3 M-1 383.3067 
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4. DOCKING STUDIES OF SYNTHESIZED COMPOUNDS 
 
a) Rigid docking  using GLIDE 10.2 version 
 Crystal structure of BTK (PDB ID: 5FBN)   was used for the study. Structure-
based docking studies were carried out using GLIDE version 10.2 .The protein 3D 
structure was downloaded from the protein databank (PDB), the solvent molecules in the 
protein were removed and hydrogen atoms were added to the protein using Cerius2 
module . . Fifty distinct poses of each  synthesized compounds IAA, IPAA, IHA, ISA, 
IPABA were generated and docked against  the hydrophobic binding pocket  of Butyro 
tyrosine kinase Tyr 461, Asp 426, Phe 540,Asp539 and Thr 474 of BTK  active site. 
Glide fitness scores  were found to correlate well with the biological activities it was also 
observed that hydrogen bond interactions play a major role in deciding the fitness score 
of the molecule.  
b) Flexible docking using Argus lab 4.1 
 FlexibleDocking was performed on 33 BTK inhibitors using Argus 4.1 the 
binding region was defined using a grid 32 X 32 X 32 box centered on the centroid of the 
target. Default setting were used for all the remaining parameters. Fifty distinct poses of 
each synthesized compounds IAA, IPAA, IHA, ISA, IPABA were generated. The 
hydrophobic binding pocket of Butyro tyrosine kinase is made up of key residues Tyr 
461, Asp 426 and Thr 474 was considered as active site for docking and saved  the 
docked protein ligand complexes as brook haven pdb.files (*.pdb).Inspecting docking 
results consisting of high scoring poses found by Molegro molecular viewer. A better 
understanding of the interactions is obtained by viewing the molecules in the active site. 
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RESULTS AND DISCUSSIONS 
 All the synthesized compounds IAA, IPAA, IHA, ISA, IPABA were docked 
against enzyme target  BTK (PDB ID: 5FBN) to study their binding interactions by using 
GLIDE 10.2 and snapshots, docking results were given below 
IAA IHA 
  
IPABA IPAA 
  
 
ISA 
    
 
Fig.No.23: The binding conformation and Hydrogen bonding,  
pi-pi static interaction of docked ligands 
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IAA IHA 
  
IPABA IPAA 
  
 
       ISA 
                                                     
Fig.No.24: The binding mode of the designed ligands in the active sites of BTK. The 
BTK protein is shown in ribbon model while the ligands were depicted by sticks model. 
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Table.No.23: Docking Score of synthesized compounds using Glide 10.2 
S.no  Compound code 
Docking score 
(SP - Glide       
10.2) 
Energy of 
protein 
KJ/mol 
Minimized 
energy of 
protein 
KJ/mol 
1 IPABA -6.808 -80.7430 -177.6756 
2 ISA -6.437 39.506 -39.6756 
3 IAA -7.632 25.8316 -41.4503 
4 IHA -7.770 -155.253 -155.2529 
5 IPAA -7.970 -33.3296 -115.6136 
    
Table.No.24: Type of interaction between ligand and the target proteins 
S.no 
Compound 
code 
Number of interaction 
 
Functional group involved in 
interaction 
1 IPABA 
1. Hydrogen bond 
2. Pi-Pi static  
Imidazole NH with Thr 474 
Substituent of NH with Phe 
540 
2 ISA 
1. Hydrogen bond 
2. Pi-Pi static 
Imidazole NH with Thr 474 
Aromatic acid with Phe 540 
3 IAA 
1. Hydrogen bond 
2. Pi-Pi static 
Imidazole NH with Thr 474 
Substituent of NH with Phe 
540 
4 IHA 
1. Hydrogen bond 
2. Pi-Pi static 
Imidazole NH with Asp 539 
Phenyl substituted imidazole 
with Phe 540 
5 IPAA 
1. Hydrogen bond 
2. Pi-Pi static 
Imidazole NH, substituted NH, 
O from aromatic acid  with 
Asp 539 
Aromatic acid with Phe 540 
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DOCKING STUDIES BY USING ARGUS LAB 4.1  
 All the synthesized compounds IAA, IPAA, IHA, ISA, IPABA were docked 
against enzyme target BTK (PDB ID: 5FBN) to study their binding interactions by using 
Argus lab 4.1 and snapshots ,docking results were given below 
IAA IPABA 
  
IHA IPAA 
  
 
ISA 
 
Fig.No.25: Docking view of ligands with active site 
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ISA IPABA 
  
IAA IPAA 
  
 
IHA 
             
Fig.No.26: Hydrogen bond interaction view of ligand with active site 
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IHA IPABA 
  
IAA IPAA 
  
 
ISA 
 
Fig.No.27: Interaction diagram of ligand with active site of target 
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Table.No.25: Docking Score and interaction of ligands with active site of target using 
Argus lab 4.1 
S.No Compound 
code 
Enery Score  
(Kcal/mol) 
Type of 
interaction 
Groups involved in 
the interaction 
 
 
1 
 
 
IAA 
 
 
-11.6513 
Hydrogen bond (1) 
 
Stearic (7) 
Imidazole NH with 
Thr 474 
 
Lys 430, Ile 432, 
Leu 542, Thr 474, 
Met 477, Tyr 476, 
Leu 528. 
 
 
 
2 
 
 
 
IPABA 
 
 
 
-11.46 
Hydrogen bond (2) 
 
 
Stearic (5) 
Substitd NH with 
Tyr 461,  
Aromatic acid NH 
with Asp 426 
Trp 421, Tyr 461, 
Gln 424, Asp 426  
 
 
 
3 
 
 
ISA 
 
 
-11.6045 
 
 
Stearic (5) 
 
Val 427, Tyr 425, 
Trp 421, Ile 397, Ile 
473. 
 
 
4 
 
 
IPAA 
 
 
-12.7548 
Hydrogen bond (1) 
 
Stearic (6) 
Imidazole NH with 
Tyr 461  
Trp 421, Ile 397, Val 
427, Ile 473, Tyr 
425, Asp 426. 
 
5 
 
IHA 
 
-12.0101 
 
Stearic (4) 
Trp 421, Val 427, 
Tyr 461, Trp 395.  
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V. C. EVALUATION STUDIES 
 
i) IN-VITRO ANTI-ARTHRITIC ACTIVITY 
MATERIALS
56 
Phosphate buffer saline (PH 6.3) 
 Transfer 8 g of sodium chloride, 0.2 g of potassium chloride, 1.44 g of disodium 
hydrogen phosphate and 0.24 g of potassium dihydrogen phosphate to a one litre 
standard flask and dissolve in 800 ml of distilled water. Adjust the pH to 6.3 using 1N 
Hydrochloric acid and make up the volume to 1000 ml with distilled water. 
 
Bovine serum albumin (5%) 
 Dissolved 5g of bovine serum albumin in 100 ml water 
 
METHOD 
Test solution: 0.5 ml - It consists of 0.45 ml of (5% W/V) Bovine Serum Albumin and 
0.05 ml of test solution of various concentrations from10 μg/ml to 1000 μg/ml 
 
Test control solution: 0.5 ml - It contains 0.45 ml of (5% W/V) Bovine Serum Albumin 
and 0.05 ml of distilled water. 
 
Product control 0.5 ml - It contains 0.45 ml of distilled water and 0.05 ml of test 
solution 
 
Standard solution 0.5 ml – It contains 0.45 ml of (5% W/V) Bovine Serum Albumin 
and 0.05 ml of standard drug at different concentrations. The test and standard drug 
concentration ranging from 50 to 1000 μg/ml (50 μg, 100 μg, 200 μg, 400 μg, 600 μg,  
800 μg, and 1000 μg) were taken and the pH was adjusted to 6.3 using 1N Hydrochloric 
acid. The samples were incubated at 37
o
C for 20 min and heated at 57
o
C for 3 min. After 
cooling 2.5 ml of phosphate buffer was added to all the above solutions. The turbidity 
was measured at 416 nm using UV-Visible spectrophotometer. The control represents 
100% protein denaturation. The percentage inhibition of protein denaturation was 
calculated using the formula. 
 
% of inhibition = 100 - [OD of test solution- OD of product control]   X 100 
                                                        OD of test control 
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RESULTS AND DISCUSSION 
Table.No.26: Effect of synthesized compounds and Diclofenac sodium on inhibition of 
protein denaturation method 
S. 
no 
Concentration 
µg/ml 
% of inhibition of protein denaturation 
Diclofenac 
sodium 
IAA IPAA IHA ISA IPABA 
1 50 33.36±0.02 32.57±0.06 36.43±0.04 38.28±0.04 41.36±0.02 43.36±0.02 
2 100 42.44±0.07 46.43±0.05 45.76±0.03 47.67±0.07 
 
48.17±0.09 
 
 
50.44±0.05 
3 200 46.81±0.08 53.18±0.04 52.23±0.02 55.81±0.05 56.36±0.02 57.81±0.04 
4 400 53.54±0.05 56.45±0.04 55.65±0.07 56.36±0.02 59.50±0.05 61.54±0.08 
5 600 64.79±0.04 63.97±0.05 
 
63.54±0.04 
 
65.73±0.03 
 
67.79±0.05 
 
68.79±0.07 
6 800 71.65±0.06 70.55±0.04 71.25±0.06 
 
74.58±0.05 
 
76.89±0.03 80.65±0.04 
7 1000 75.26±0.03 76.13±0.03 78.36±0.02 79.43±0.04 80.56±0.06 85.26±0.03 
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Graph.No.1: Percentage inhibition Vs Concentration 
Blue- IAA, Red- IPAA, Green- IHA, Violet- ISA, Sky blue- IPABA, Cyan red- 
Diclofenac sodium 
 
 The In-Vitro Anti-arthritic activity has been carried out using most popular 
inhibition of protein denaturation method. The synthesized compounds showed 
significant activity at various concentration ranging from 50-1000 µg/ml. From the 
results the minimum percentage inhibition of protein denaturation of test compounds 
IAA, IPAA, IHA, ISA, IPABA and standard (Diclofenac sodium) were observed as 
33.36 , 32.57, 36.43, 38.28, 41.36, 43.36 at 50 µg/ml and the maximum inhibitory 
concentration of synthesized compounds were observed  as 75.26 %, 76.13 %, 78.36 %, 
79.43 %, 80.56 %, 85.26 % at 1000 µg/ml as shown in Table.No.26. At 1000 µg/ml 
concentration of the synthesized compounds, IPABA was found to effectively inhibit the 
protein denaturation similar to that of standard drug Diclofenac sodium. Hence, out of all 
five different synthesized imidazolyl derivatives , compound IPABA was alone  
considered for further Anti- rheumatoid arthritic evaluation by performing in-vivo 
method.  
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PHARMACOLOGICAL EVALUATION 
a) MATERIALS64,65 
Animals  
      Wistar rats (200-300g) either sex were acclimatized for 7 days under standard 
husbandry conditions, i.e. room temperature 25±10 C, relative humidity 45-55% and 
light/dark cycle 12/12 hrs. The experimental protocols were approved by the Institutional 
Animal Ethical Committee (IAEC) of CPCSEA (Committee for the Purpose of Control 
and Supervision of Experiments on Animals) (Regd. No: IAEC/MMC/04/2016)  
 
Husbandry Practices Caging 
 Polypropylene rat cages covered with stainless steel grid top were Autoclaved 
clean rice husk was used as the bedding mate  
 
Water Bottle  
 Each cage was supplied with a polypropylene water bottle with a stainless steel 
nozzle. 
 
Housing 
 Single rat per cage  
 
Room Sanitation  
 Each day, the floor of the experiment room was swept and all work tops and the 
floor were mopped with a disinfectant solution. 
 
Animal Identification 
 Each rat was uniquely numbered on the tail using a tattoo machine. Appropriate 
labels were attached to the cages indicating the study number, sex, and dose, type of 
study, cage number and animal number. 
 
b) METHODS 
i) Acute oral toxicity (Acute toxic class method in wistar rats) 
ii) In-vivo anti-rheumatoid arthritis activity. 
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i) ACUTE ORAL TOXICITY (ACUTE TOXIC CLASS METHOD IN WISTAR RATS) 
 Acute oral toxicity defines to the adverse effects occurring following oral 
administration of single dose of substances or multiple doses given within 24 hrs.  
 
The different methods used to evaluate the acute oral toxicity studies are as follows, 
i) Fixed dose procedure (OECD Guidelines-420) 
ii) Acute toxic class method (OECD Guideline-423) 
iii) Ups and Down procedure (OECD Guideline- 425) 
  Our study was done following acute toxic class method (OECD-423) 
 
OECD Guideline-423 
 OECD guidelines for the testing of chemicals are periodically reviewed in the 
light of scientific progress or changing assessment practices. The original guideline 423 
was adapted in March 1996 as the second alternative to the conventional acute toxicity 
test, described in the test guideline 401. Based on the recommendations of several expert 
meetings, revision was considered timely because international agreement has been 
reached on harmonized LD50 cut-off value for the classification of chemical substances, 
which differ from the cut-off recommended in the 1996 version of the guideline and 
testing in one sex (usually female) is now considered sufficient. 
 
A. Acute toxic class method 
In the present study the oral toxicity of the synthesized compounds were performed by 
acute toxic class method. In this methods the toxicity of the synthesized compounds were 
tested using a stepwise procedure, each step using three rats of a single sex. The various 
concentration of test drug as per OECD guidelines are as follows, The wistar rats were 
fasted overnight prior to dosing (food but not water should be withheld). Following the 
period of fasting the animal should be weighed and the synthesized compounds    
administered orally at the dose of 2000 mg/kg body weight. Animals were observed 
individually after dosing atleast during the first 4 hrs and daily thereafter, for a total of 14 
days. As no mortality was observed with the above doses, a series of doses 250 and 500 
mg/kg body weight were selected for the further pharmacological evaluation. The test 
procedure with starting doses of 2000 mg/ kg body weight as per OECD- 423 guidelines 
was shown as follows, 
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Fig.No.28: Treatment protocol for the acute toxicity study (OECD-423) 
ii) IN-VIVO ANTI-RHEUMATOID ARTHRITIC ACTIVITY 
1. Animal 
 Protocol of the study was passed by Institutional Ethics Committee of Madras 
Medical College, Chennai-03. The study was carried out with adult Wistar rats 
(Male/Female) weighing 100-200 g. Animal were acclimatized to the experimental 
conditions in cages and kept under a standard environmental condition (22 + 3
0
C; 12/12 
hr light/dark cycle). Rats were allowed to feed and water. 
2. Induction of CFA and Drug treatment 
Adult wistar rats with an initial body weight of 100-200g were taken, and divided into 
five groups each containing 6 animals. On zero day, all rats were injected into the sub 
plantar region of left hind paw with 0.1 ml of Complete Freund’s Adjuvant. This consist 
of Mycobacterium butyricum suspended in heavy paraffin oil by through grinding with 
mortar and pestle to give a concentration of 6 mg/ml. Dosing with test and standard 
compound was started on zero day and continued for 12 days according to the following 
schedule: group I: Normal control (Distilled water), Group II: Disease control 
(suspension of 1% CMC), Group III: Dexamethasone (5 mg/kg, IP. Standard), Group IV: 
Test compound  IPABA (Low Dose) Group V: Test compound IPABA (High dose). 
From day 13
th
 to 21
st
, the animals were not dosed with the test compound or the standard. 
Then the following parameter were measured and tabulated. 
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Table.No.27: Grouping of animals 
Sr. 
No 
Group 
No. of 
Animals 
Treatment Dose 
1 
Group I 
Normal Control 
6 
Normal Saline 
neither FA treated nor drug 
treated 
---- 
2 
Group II 
Disease Control 
6 
Freund’s adjuvant (CFA) 
Distilled water 
0.1ml 
(6mg/ml) 
3 
Group III 
Standard Treatment 
6 Dexamethasone + CFA 
5mg/kg 
CFA 0.1ml 
4 
Group IV 
Cpd-IPABA(low dose) 
6 Test compound + CFA 
100mg/kg 
CFA 0.1ml 
5 
Group V 
Cpd-IPABA(high 
dose) 
6 Test compound + CFA 
200mg/kg 
CFA 0.1ml 
 
3. Evaluation of development of Arthritis 
 Rats were inspected daily for the onset of arthritis characterized by edema in the 
paws. The incidence and the severity of arthritis were evaluated using a system of 
arthritic scoring. Measurement of  bi-hind paw volumes every 3 days, when arthritic 
signs were first visible. Animals were observed for presence or absence of nodules in 
different organs like ear, fore paw, hind paw, nose and tail. Animal were scored 0 for 
absence of nodules and 1 for its presence.  Score 5 was given as the potential maximum 
of arthritic score per animal. Hind paw volume was measured using plethysmometer. 
Paw volumes of both hind limbs were recorded from day of Treatment started to 21st day 
at three day interval using mercury column plethysmometer. 
 
4. Rheumatoid Factor 
 The latex turbidimetry method was used in the present study using RF turbilatex 
kit of SPINREACT Company. Calibration was carried out for linear range up to 100 
IU/ml. The reading of RF factor of all the groups obtained was compared with the 
control animals and was expressed as IU/ml RF. 
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5. Radiography  
 Wistar rats were sacrificed on 21st day of CFA administration and legs were 
removed and placed on formalin containing plastic bags. This plastic bag was kept at a 
distance of 90 cm from the X-ray source and Radiographic analysis of arthritic and 
treated animal hind paw were performed by X-ray machine with a 300-mA exposition 
for 0.01 s. An investigator blinded for the treatment regimen performed radiograph score. 
Which were used as a quantal test for bone necrosis. The following radiograph criteria 
were considered .Radiographs were carefully examined using a stereo microscope and 
abnormalities were graded as follows:  
(i) Periosteaic reaction, 0 - 3 (None, Slight, Moderate, Marked); 
(ii) Erosions, 0 - 3 (None, Few, Many Small, Many Large); 
(iii) Joint space narrowing, 0 - 3 (None, Minimal, Moderate, Marked); 
(iv) Joint space destruction, 0 - 3 (None, Minimal, Extensive, Ankylosis). 
(v) Bone destruction was scored on the patella as described previously. 
6. Effect on Spleen-Index 
At the end of the experiment, after sampled for serum, all mice were sacrificed by ether 
anesthesia. All the spleens of mice were weighed immediately after dissection. The 
spleen indexes were calculated by using the following formula: 
 
   Spleen weight of CFA rat / Body weight of CFA rat  
Spleen Index =        ________________________________________________ 
   Spleen weight of normal rat / Body weight of normal rat  
 
 
7. Total leukocyte Count and Neutrophile count 
 Blood samples were collected by puncturing the retro-orbital plexus into 
heparanized vials and analysed for total leucocyte counts (TLC) and differential 
leucocyte counts (DLC) 
 
8. Histological Processing and Assessment of Arthritis Damage 
 Rats were sacrificed by ether anesthesia. Knee joints were removed and fixed for 
4 days in 4% formaldehyde. After decalcification in 5 % formic acid, the specimens were 
processed for paraffin embedding tissue sections (7 μm thick) and were stained with 
haematoxylin, eosin or safranin. An experienced pathologist, unaware of the different 
drug treatments scored the condition of tibiotarsal joints. Histopathological changes were 
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scored using the following parameters. Infiltration of cells was scored on a scale from 0 
to 3, depending on the amount of inflammatory cells in the synovial tissues. 
Inflammatory cells in the joint cavity were graded on a scale from 0 to 3 and expressed 
as exudate. A characteristic parameter in arthritis is the progressive loss of articular 
cartilage. This destruction was separately graded on a scale from 0 to 3, ranging from the 
appearance of dead chondrocytes (empty lacunae) to complete loss of the articular 
cartilage. Bone erosion was scored on a scale ranging from 0 to 3, ranging from no 
abnormalities to complete loss of cortical and trabecular bone of the femoral head. 
Cartilage and bone destruction by pannus formation was scored ranging from 0, no 
change; 1- mild change (pannus invasion within cartilage); 2-moderate change (pannus 
invasion into cartilage/subchondral bone); 3- severe change (pannus invasion into the 
subchondral bone) and vascularity (0- almost no blood vessels; 1- a few blood vessels; 2- 
some blood vessels; 3-many blood vessels). Histopathological changes in the knee joints 
were scored in the femur region on 5 semi-serial sections of the joint, spaced 70 μm 
apart. Scoring was performed on decoded slides by two observers, as described earlier. 
 
9. Statistical analysis 
 Statistical analysis of difference between groups was evaluated by one-way 
ANOVA followed by student t test. The values P < 0.05 were regarded as significant and 
the values P< 0.01 were considered as highly significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PHARMACOLOGICAL EVALUATION 
 
90 
 
 
RESULTS AND DISCUSSION 
A. Oral Acute Toxicity Study OECD-423 
Oral acute toxicity of newly synthesized imidazolyl hetero cycles such as IPAA, ISA, 
IPABA, IHA, IAA were studied and the results were tabulated. 
Table.No.28: Observation in Oral Acute Toxicity Study (OECD-423)  
S. 
No 
Observation 
For 30 
mins 
4 hrs 24 hrs 48 hrs 7 day 14 day 
1 Sedation Absent Absent Absent Absent Absent Absent 
2 Excitation Absent Absent Absent Absent Absent Absent 
3 Jumping Normal Normal Normal Normal Normal Normal 
4 Writhing Absent Absent Absent Absent Absent Absent 
5 Scratching Absent Absent Absent Absent Absent Absent 
6 Grooming Absent Absent Absent Absent Absent Absent 
7 Aggression Absent Absent Absent Absent Absent Absent 
8 Ptosis Absent Absent Absent Absent Absent Absent 
9 Loss of writhing reflux Absent Absent Absent Absent Absent Absent 
10 Lose of pinel reflux Absent Absent Absent Absent Absent Absent 
11 Lose of coreneal reflux Absent Absent Absent Absent Absent Absent 
12 Excess Salivation Absent Absent Absent Absent Absent Absent 
13 Lacrimation Absent Absent Absent Absent Absent Absent 
14 Skin & fur Normal Normal Normal Normal Normal Normal 
15 Color of eye Normal Normal Normal Normal Normal Normal 
16 Tremors Absent Absent Absent Absent Absent Absent 
17 Diarrhea Absent Absent Absent Absent Absent Absent 
18 Coma Absent Absent Absent Absent Absent Absent 
19 Inflammation Absent Absent Absent Absent Absent Absent 
20 Urination Absent Absent Absent Absent Absent Absent 
 
 In acute toxicity study test, no mortality (sign of toxicity) was observed for all the 
selected doses during the study. The acute toxicity studies showed that the non-toxic 
nature of the newly synthesized imidazolyl heterocycles such as IPAA, ISA, IPABA, 
IHA, IAA was up to the level of 2000 mg/kg body weight selected doses. 
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B. In-Vivo Anti- Arthritic activity 
 The results were obtained after daily administration of the test doses 100 mg/kg, 
200 mg/ kg and standard drug 5mg/ kg in this experimental protocol arthritis revealed 
that the test compound IPABA exerted the effective anti-arthritic activity. 
Food pad thickness / Paw volume 
The hind paw injected with Complete freund’s adjuvant became gradually 
swollen and reached its peak at 21
st
 day .The result obtained for the two different doses 
of the test compound and the standard drug (Dexamethasone 5mg/ kg) in the Complete 
freund’s adjuvant induced paw edema test at specific time intervals. When compared 
with Normal Control rats, the Disease Control rats showed significant increase (P < 
0.001) in the paw volume after seven days of sub plantar CFA administration. In the 
primary phase of the arthritis i.e. form day 4 to 7, there was non-significant deceased in 
the paw volume was observed. Rats treated with test compound (100 and 200 mg/kg) 
showed significant and dose-dependent attenuation in paw volume from day 12 to 21 
onward as compared to Disease Control rats. Rat treated with Dexamethasone (5 mg/kg) 
significantly decreased (P < 0.001) paw volume from day 12 to 21 to as compared to 
control rats. Rats treated with test compound IPABA (100 and 200 mg/kg) was found to 
have  effective anti-arthritic activity.  
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Table.No.29: Effect of Foot pad thickness 
Treatment 
Mean foot pad thickness (mm) 
0 day 3
th
 day 7
th
 day 14
th
 day 21
st
 day 
Group I 
(NC) 
4.51± 0.003 4.41±0.003 4.31±0.003 4.76±0.02 4.26±0.001 
Group II 
(DC) 
4.23±0.003*
** 
10.01± 
0.003*** 
11.13± 
0.005*** 
11.55± 
0.002*** 
11.8± 
0.002*** 
Group III 
(STD) 
4.1±0.04*** 
7.41± 
0.04*** 
6.53± 
0.03*** 
5.53± 
0.02*** 
5.06± 
0.02*** 
Group IV 
(Cpd-IPABA 
low dose) 
4.56±0.034*
** 
8.42± 
0.054*** 
7.28± 
0.02*** 
6.73± 
0.04*** 
5.16± 
0.09*** 
Group V 
(Cpd- 
IPABAhigh 
dose) 
4.15±0.03**
* 
8.16± 
0.02*** 
8.43± 
0.02*** 
7.2± 
0.02*** 
6.02± 
0.03*** 
 
 
N= 6, values were expressed as Mean ± SEM, ***p value <0.001 significant, NC- 
Normal control. DC- Disease control; STD- Standard group; Cpd- Compound IPABA.  
 
 
Graph.No.2: Foot pad thickness 
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Effect of Average body weight 
Changes in body weight was also recorded to evaluate anti- arthritic potential of 
synthesized compound IPABA. Rats treated with Dexamethasone (5mg/kg) shows 
significantly increased in body weight (P< 0.001) synthesized compound IPABA 
100mg/kg and 200mg/kg also showed significant changes in body weight with value of  
P<0.001 when compared with disease control. 
 
Table.No.29: Effect of Average body weight 
Treatment 
Average Body weight 
0 day 3
rd
 day 7
th
 day 14
th
 day 21
st
 day 
Group I 
(NC) 
278.66±  
0.32 
278.32± 
0.43 
275.50± 
0.98 
274.60± 
0.12 
272.93± 
0.72 
Group II 
(DC) 
265.19± 
0.34** 
223.16± 
0.56** 
218.40± 
0.34** 
196.31± 
0.72** 
182.41± 
0.45** 
Group III 
(STD) 
297.18± 
0.84** 
282.16± 
0.96** 
277.40± 
0.24** 
287.31± 
0.92** 
272.41± 
0.32** 
Group IV 
(Cpd low 
dose) 
268.16± 
0.764** 
241.16± 
0.56** 
269.40± 
0.84** 
252.31± 
0.42** 
251.41± 
0.62** 
Group V 
(Cpd high 
dose) 
271.13± 
0.24** 
252.16± 
0.87** 
244.40± 
0.97** 
242.31± 
0.32** 
244.41± 
0.92** 
N= 6, values were expressed as Mean ± SEM, ***p value <0.001 significant, NC- 
Normal control. DC - Disease control; STD - Standard group; Cpd - Compound IPABA.  
 
 
Graph.No.3: Average body weight 
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Effect of Hematological Parameter 
The changes in hematological parameters in adjuvant induced arthritic rats are 
shown in Table.No.30. There was a significant (p < 0.001) decrease in RBC count and 
hemoglobin and increase in WBC count and ESR of arthritic rats as compared to control 
rats. Rats treated with Dexamethasone (5mg/kg) showed changes in the haematological 
function when compared with disease controlled rats.  Rats treated with synthesized 
compound IPABA 100mg/kg and 200mg/kg also shows significant changes in body 
weight with  value of P<0.001. 
 
Table.No.30: Effect of Hematological Parameter 
Treatment 
Hb 
(g/dl) 
RBC 
(x10
6/
mm
3
) 
WBC 
(x10
3/
mm
3
) 
ESR 
(mm) 
Group I 
(NC) 
13.98 ± 0.040 6.51± 0.030 7.35 ± 0.002 4.65 ± 0.034 
Group II 
(DC) 
10.05±0.034*** 3.7± 0.025*** 11.48 ± 0.030*** 10.2 ±  0.025*** 
Group III 
(STD) 
11.5± 0.025*** 6.2 ± 0.025*** 8.9 ± 0.025*** 6.71±0.030*** 
Group IV 
(Cpd low 
dose) 
10.8± 0.025*** 5.5 ± 0.025 *** 9.3 ± 0.03*** 8.46±0.021*** 
Group V 
(Cpd high 
dose) 
9.25± 0.004*** 4.76 ± 0.021*** 8.5 ± 0.02*** 6.11 ±0.03*** 
N= 6, values were expressed as Mean ± SEM, ***p value <0.001 significant, NC- 
Normal control. DC - Disease control; STD - Standard group; Cpd - Compound IPABA.  
 
 
Graph.No.4: Hematological Parameter 
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Arthritic Index and Rheumatoid Factor 
 Sub plantar administration of CFA results in significant increased (P < 0.001) in 
arthritic score in all arthritic treated rats as compared to control rats. Albino rats treated 
with synthesized compound IPABA showed significant and dose dependent decreased in 
arthritic score (P < 0.001) as compared to arthritic diseased rats. 
 
Table.No.31: Effect of Arthritic Index 
Treatment Arthritic Index 
Group I (NC) 0.00± 0.000 
Group II (DC) 3.76 ± 0.24*** 
Group III (STD) 1.32 ± 0.25*** 
Group IV (Cpd low dose) 1.86 ± 0.32*** 
Group V (Cpd high dose) 2.63 ± 0.18*** 
N= 6, values were expressed as Mean ± SEM, ***p value <0.001 significant, NC- 
Normal control. DC - Disease control; STD - Standard group; Cpd - Compound IPABA.  
 
 
    Graph.No.5: Arthritic Index 
 
 Arthritic index and Rheumatoid Factor were significantly decreased in treatment 
with test compound (100, 200 mg/kg) and Dexamethasone (5mg/ kg) treated animal as 
compared to disease control treatment as shown in Graph.No.5. 
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Table.No.32: Effect of Rheumatoid Factor 
Treatment Rheumatoid Factor 
Group I (NC) 9.20± 0.82 
Group II (DC) 28.83 ± 3.39*** 
Group III (STD) 12.62 ± 2.65*** 
Group IV (Cpd low dose) 15.1 ± 0.32*** 
Group V (Cpd high dose) 18.26± 0.18*** 
 
N= 6, values were expressed as Mean ± SEM, ***p value <0.001 significant, NC- 
Normal control. DC - Disease control; STD - Standard group; Cpd - Compound IPABA.  
 
 
Graph.No.6: Rheumatoid Factor 
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Spleen Index 
The spleen provided a readily available source of cells known to be involved in 
animals. Increased cellularity in the spleen of arthritic rats engendered interest as to the 
potential for concomitant classical antibody formation synthesized compound IPBA 
Inhibit splenomegaly, which can enhance inhibitory effect of cells shown in Graph.No.7. 
Spleen Index were significant increased (P < 0.001) in all arthritic treated rats as 
compared to control rats. The Spleen Index reduction in synthesized compound IPABA 
(100 & 200 mg/kg) and Dexamethasone (5 mg/kg) treated rats were significantly (P < 
0.001)   lesser than that of arthritic diseased rats.  
Fig.No.33: Effect of Spleen Index 
 
N= 6, values were expressed as Mean ± SEM, ***p value <0.001 significant, NC- 
Normal control. DC - Disease control; STD - Standard group; Cpd - Compound IPABA.  
 
 
Graph.No.7: Spleen Index 
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Treatment Groups (mg/kg) 
Spleen Index
Treatment Spleen  Index 
Group I (NC) 7.2± 0.32 
Group II (DC) 11.76 ± 0.24*** 
Group III (STD) 6.32 ± 0.55*** 
Group IV (Cpd low dose) 8.86 ± 0.22*** 
Group V (Cpd high dose) 9.83 ± 0.18*** 
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Radiography 
 Bone destruction, which is a common feature of adjuvant arthritis was examined 
by radiological analysis. Treated rats had developed definite joint space narrowing of the 
intertarsal joints, diffuse soft tissues swelling that includes the digits, diffuse 
demineralization of bone, marked periosteal thickening and cystic enlargement of bone 
and extensive erosions produced narrowing or pseudo widening of all joints space. In 
contrast, rats treated with synthesized compound IPABA attenuate abnormalities 
consisted of asymmetric soft tissue swelling and small erosions, periosteal thickening 
and minimal joint space narrowing areas of the paws and the result were shown below. 
Despite a similar chemical course of arthritis, disease control rats suffered more 
pronounced bone destruction than synthesized compound IPABA treated animals as 
shown on radiograph taken on 21
st
 day in CFA induced arthritis.   
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Group I (Normal control) Group II (Disease control) 
  
Group III (Standard control) Group IV Test (Low dose) 
  
 
   
Group IV Test (High dose) 
 
Fig.No.29: Effect of synthesized compound IPABA on tibiotarsal joints 
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Histopathology 
 Synthesized compound IPABA treated animals showed more pronounced 
decrease in bone density, destruction of bony structure, as compare to disease control as 
shown in Fig.No.30. Abrogation of disease progression by synthesized compound 
IPABA was further supported by the Histopathologic analysis of the joints from these 
animals. Rats that had been treated with test compounds at the time CFA immunization 
showed no histological abnormalities with no evidence of cartilage erosion in their joints 
in contrast to the disease control rats that displayed completely destroyed joint 
architecture as shown below 
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Group I (Normal control) Group II (Disease control) 
  
Group III (Standard control) Group IV Test (Low dose) 
  
Group IV Test (High dose) 
 
Fig.No.30: Histopathology of joints indicates treatment with  
synthesized compound IPABA prevent bone erosion 
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When the synthesized compound IPABA was screened for the In-vivo Anti-rheumatoid 
arthritic activity by adjuvant induced method in which the following parameters were 
observed and reported as follows 
 In hematological parameter, the result of P values obtained in one way ANOVA, 
synthesized compound IPABA 100mg/kg, 200mg/kg was found to decreases the WBC, 
ESR counts and increases the Hemoglobin, RBC counts with the ***P value < 0.001 and 
was found to be reduce the rheumatoid factor and compared with  that of standard 
Dexamethasone 5mg/kg. 
 In spleen index, the result of P values obtained in one way ANOVA, synthesized 
compound IPABA 100mg/kg, 200mg/kg was found to inhibit the splenomegaly with the 
***P value < 0.001 and was found to be reduce the spleen index and also compared with 
standard Dexamethasone 5mg/kg. 
 In radiography, the result of P values obtained in one way ANOVA, synthesized 
compound IPABA 100mg/kg, 200mg/kg was found to increases the joint space and 
decreases the erosion in joints with the ***P value < 0.001 and proved to be significant 
when compared with standard Dexamethasone 5mg/kg. 
 In histopathology, the result of P values obtained in one way ANOVA, 
synthesized compound IPABA 100mg/kg, 200mg/kg was found to reduces the 
destruction of bony structure and increased the bone density with the ***P value < 0.001  
significantly as   that of standard Dexamethasone 5mg/kg. 
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VII. SUMMARY AND CONCLUSION 
 
 Over the last few years, BTK has been considered as therapeutic target for 
selective B-Cell inhibition in the treatment of Rheumatoid Arthritis. Though many BTK 
inhibitors are reported and few are in clinical trials, none are FDA approval. Based on 
the literature review, all the existing BTK inhibitors found to possess mainly five 
Pharmacophoric features like 1HBAL Hydrogen Bond Acceptor Lipid, 1HBD Hydrogen 
Bond Donor, 3 HYP Hydrophobic. Hence, a scaffold library has been generated with 33 
newly designed ligands which were screened with high docking score against BTK using 
GLIDE 10.2 and further optimized by Drug likeness properties such as Lipinski rule of 
five and ADMET properties.  
 
 Based on the synthetic feasibility, scaffold containing 4,5 di-phenyl 2-substituted 
imidazole nucleus like Ligand 6, Ligand 9, Ligand 14, Ligand 13 and Ligand 12  were 
selected for synthesis. All the selected ligands were chemically synthesized involving 
Radiswieski reaction and condensation with different aromatic carboxylic acids. Five 
different synthesized  compound such as IPABA, ISA, IAA, IHA, IPAA were prepared 
and its purity were established by singe spot on TLC plate. The chemical nature of the 
synthesized compounds were characterized by Melting point determination and different 
spectral studies such as IR, 
1
H NMR, 
13
C NMR and GC-MS analysis. Then the  
synthesized compounds were subjected to molecular docking studies using both GLIDE 
10.2 and ARGUSLAB 4.1. 
  
 All the synthesized compounds were subjected to In-vitro Anti-Arthritic activity 
by Protein inhibition assay method at different concentration 50 μg, 100 μg, 200 μg, 400 
μg, 600 μg, 800 μg, 1000 μg and also compared with standard Diclofenac sodium. The 
synthesized derivatives IPABA, ISA, IAA, IHA, IPAA were found to significantly  
inhibit the protein denaturation. Compounds   IPABA was found to effectively inhibit the 
denaturation of protein at a minimum concentration of 50 μg/ml and maximum 
concentration of 1000 μg/ml as equipotent as that of Diclofenac sodium.  
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 Oral acute toxicity studies were performed as per OECD guidelines 423 to access 
the toxicity and also to fix the dose. The LD50 value of the test compounds IPABA, ISA, 
IAA, IHA, IPAA does not found to 2000 mg/kg body weight and also no mortality was 
observed.  
 
 The most potent effective synthesized compound  IPABA from the previous In-
Vitro anti-arthritic screening was selected and subjected to In-Vivo anti rheumatoid 
arthritic activity. When the synthesised compound IPABA was screened at  the 
concentration of 100mg/kg and 200mg/kg for  in-vivo adjuvant induced arthritic activity, 
it was found to  be equally effective  and highly significant  (***P value < 0.001 )  as  
that of standard drug dexamethasone at 5 mg/kg as proved statistically by one-way 
ANOVA analysis. 
 
CONCLUSION 
 Drug design approach as well as clinical studies have revealed that the tyrosine 
kinase (Bruton’s tyrosine kinase) have a crucial role in the inhibition of B-cells for 
treatment of Rheumatoid Arthritis. The present study also provides important structural 
insights of 4,5 di-phenyl 2 substituted imidazole moieties in designing better BTK 
inhibitor as potent anti- rheumatoid arthritic agents and thus the synthesized compound 
IPABA (4-amino-N-[(4,5-diphenyl-1H-imidazol-2-yl)methyl]benzamide) was found to 
be an effective BTK inhibitor for treatment of rheumatoid arthritis.  
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